documents incorporated reference parts portions registrants proxy statement annual meeting shareholders filed within days close iii registrants fiscal year proxy statement incorporated reference report reportitem part business general segments business geographic areas raw materials patents trademarks seasonality competition environment regulation employees human capital management available information risk factors b unresolved staff comments properties legal proceedings mine safety disclosures executive officers registrant part ii market registrants common equity related stockholder matters issuer purchases equity securities reserved managements discussion analysis results operations financial condition quantitative qualitative disclosures market risk financial statements supplementary data changes disagreements accountants accounting financial disclosure controls procedures b information c disclosures regarding foreign jurisdictions prevent inspections part iii directors executive officers corporate governance executive compensation security ownership certain beneficial owners management related stockholder matters certain relationships related transactions director independence principal accountant fees services part iv exhibits financial statement schedules summary signatures exhibit index cautionary note regarding forwardlooking statements annual report johnson johnsons publicly available documents contain forwardlooking statements within meaning safe harbor provisions united states private securities litigation reform act management representatives johnson johnson subsidiaries company also may time time make forwardlooking statements forwardlooking statements relate strictly historical current facts reflect managements assumptions views plans objectives projections future forwardlooking statements may identified use words plans expects anticipates estimates words similar meaning conjunction among things discussions future operations expected operating results financial performance impact planned acquisitions dispositions impact timing restructuring initiatives including associated cost savings benefits planned separation companys consumer health business companys strategy growth product development activities regulatory approvals market position expenditures forwardlooking statements based current beliefs expectations assumptions regarding future events subject uncertainties risks changes difficult predict many outside companys control investors realize underlying assumptions prove inaccurate known unknown risks uncertainties materialize companys actual results financial condition could vary materially expectations projections expressed implied forwardlooking statements investors therefore cautioned rely forwardlooking statements risks uncertainties include limited risks related product development market success competition challenges uncertainties inherent innovation development new improved products technologies companys continued growth success depend including uncertainty clinical outcomes additional analysis existing clinical data obtaining regulatory approvals health plan coverage customer access initial continued commercial success challenges companys ability obtain protect adequate patent intellectual property rights new existing products technologies united states important markets impact patent expirations typically followed introduction competing generic biosimilar products resulting revenue market share losses increasingly aggressive frequent challenges companys patents competitors others seeking launch competing generic biosimilar products increased receptivity courts united states patent trademark office decision makers challenges potentially resulting loss market exclusivity rapid decline sales relevant product sooner expected competition research development new improved products processes technologies result product process obsolescence competition reach agreement third parties collaboration licensing development marketing agreements products technologies competition based costeffectiveness product performance technological advances patents attained competitors allegations companys products infringe patents intellectual property rights third parties could adversely affect companys ability sell products question require payment money damages future royalties risks related product liability litigation regulatory activity product efficacy safety concerns whether based scientific evidence potentially resulting product withdrawals recalls regulatory action part united states food drug administration international counterparts declining sales reputational damage increased litigation expense share price impact impact including declining sales reputational damage significant litigation government action adverse company including product liability claims allegations related pharmaceutical marketing practices contracting strategies impact adverse judgment settlement adequacy reserves related legal proceedings including patent litigation product liability personal injury claims securities class actions government investigations employment legal proceedings increased scrutiny healthcare industry government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties including limited debarment government business failure meet compliance obligations compliance agreements governments government agencies could result significant sanctions potential changes applicable laws regulations affecting united states international operations including relating approval new products licensing patent rights sales promotion healthcare products access reimbursement pricing healthcare products services environmental protection sourcing raw materials compliance local regulations laws may restrict companys ability manufacture sell products relevant markets including requirements comply medical device reporting regulations requirements european unions medical devices regulation changes domestic international tax laws regulations increasing audit scrutiny tax authorities around world exposures additional tax liabilities potentially excess existing reserves issuance new revised accounting standards financial accounting standards board regulations securities exchange commission risks related companys strategic initiatives healthcare market trends planned separation companys consumer health business pricing pressures resulting trends toward healthcare cost containment including continued consolidation among healthcare providers market participants trends toward managed care shift toward governments increasingly becoming primary payers healthcare expenses significant new entrants healthcare markets seeking reduce costs government pressure companies voluntarily reduce costs price increases restricted spending patterns individual institutional governmental purchasers healthcare products services due economic hardship budgetary constraints challenges companys ability realize strategy growth including externally sourced innovations development collaborations strategic acquisitions licensing marketing agreements potential heightened costs external arrangements due competitive pressures potential expected strategic benefits opportunities planned completed acquisition divestiture company may realized may take longer realize expected potential expected benefits opportunities related past ongoing restructuring actions may realized may take longer realize expected companys ability consummate planned separation companys consumer health business timely basis companys ability successfully separate companys consumer health business realize anticipated benefits planned separation new consumer health companys ability succeed standalone publicly traded company risks related economic conditions financial markets operating internationally risks associated global operations company customers suppliers including foreign governments countries company operates impact inflation fluctuations interest rates currency exchange rates potential effect fluctuations revenues expenses resulting margins potential changes exportimport trade laws regulations policies united states countries including increased trade restrictions tariffs potential drug reimportation legislation impact international operations financial instability international economies sovereign risk possible imposition governmental controls restrictive economic policies unstable international governments legal systems impact global public health crises pandemics including novel coronavirus covid pandemic changes global climate extreme weather natural disasters could affect demand companys products services cause disruptions manufacturing distribution networks alter availability goods services within supply chain affect overall design integrity companys products operations impact armed conflicts terrorist attacks united states parts world including social economic disruptions instability financial markets risks related supply chain operations difficulties delays manufacturing internally thirdparty providers otherwise within supply chain may lead voluntary involuntary business interruptions shutdowns product shortages withdrawals suspensions products market potential regulatory action interruptions breaches companys information technology systems companys vendors could result reputational competitive operational business harm well financial costs regulatory action reliance global supply chains production distribution processes complex subject increasing regulatory requirements may adversely affect supply sourcing pricing materials used companys products potential expected benefits opportunities related restructuring actions contemplated global supply chain may realized may take longer realize expected including due required approvals applicable regulatory authorities investors also carefully read risk factors described item annual report description certain risks could among things cause companys actual results differ materially expressed forwardlooking statements investors understand possible predict identify factors consider risks described item complete statement potential risks uncertainties company undertake publicly update forwardlooking statement may made time time whether result new information future events developmentspart item business general johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products healthcare field johnson johnson holding company operating companies conducting business virtually countries world companys primary focus products related human health wellbeing johnson johnson incorporated state new jersey executive committee johnson johnson principal management group responsible strategic operations allocation resources company committee oversees coordinates activities company 's three business segments consumer health pharmaceutical medical devices within strategic parameters provided committee senior management groups us international operating companies responsible strategic plans daytoday operations companies subsidiary within business segments limited exceptions managed residents country located segments business company organized three business segments consumer health pharmaceutical medical devices additional information required item incorporated herein reference narrative tabular descriptions segments operating results item managements discussion analysis results operations financial condition report note segments business geographic areas notes consolidated financial statements included item report consumer health consumer health segment includes broad range products focused personal healthcare used skin healthbeauty overthecounter medicines baby care oral care womens health wound care markets major brands skin healthbeauty include aveeno clean clear dr cilabo neutrogena ogx product lines overthecounter otc medicines include broad family tylenol acetaminophen products sudafed cold flu allergy products benadryl zyrtec allergy products motrin ib ibuprofen products nicorette smoking cessation products outside us zarbees products inspired nature pepcid line acid reflux products baby care includes johnsons aveeno baby line products oral care includes listerine product line major brands womens health outside north america stayfree carefree sanitary pads ob tampon brands wound care brands include bandaid brand adhesive bandages neosporin first aid product lines products marketed general public sold online ecommerce retail outlets distributors throughout world november company announced intention separate companys consumer health business intention create new publicly traded company company targeting completion planned separation months initial announcement pharmaceutical pharmaceutical segment focused six therapeutic areas immunology eg rheumatoid arthritis psoriatic arthritis inflammatory bowel disease psoriasis infectious diseases eg hivaids covid neuroscience eg mood disorders neurodegenerative disorders schizophrenia oncology eg prostate cancer hematologic malignancies lung cancer bladder cancer cardiovascular metabolism eg thrombosis diabetes macular degeneration pulmonary hypertension eg pulmonary arterial hypertension medicines segment distributed directly retailers wholesalers distributors hospitals healthcare professionals prescription use key products pharmaceutical segment include remicade infliximab treatment number immunemediated inflammatory diseases simponi golimumab subcutaneous treatment adults moderate severe rheumatoid arthritis active psoriatic arthritis active ankylosing spondylitis moderately active severely active ulcerative colitis simponi aria golimumab intravenous treatment adults moderate severe rheumatoid arthritis active psoriatic arthritis active ankylosing spondylitis active polyarticular juvenile idiopathic arthritis pjia people years age older stelara ustekinumab treatment adults children moderate severe plaque psoriasis adults active psoriatic arthritis adults moderately severely active crohn 's disease treatment moderately severely active ulcerative colitis tremfya guselkumab treatment adults moderate severe plaque psoriasis active psoriatic arthritis janssen covid vaccine authorized use emergency use authorization eua active immunization prevent coronavirus disease covid caused severe acute respiratory syndrome coronavirus sarscov individuals years age older edurant rilpivirine prezista darunavir prezcobix rezolsta darunavircobicistat antiretroviral medicines treatment human immunodeficiency virus hiv combination antiretroviral products symtuza darunavircobicistatemtricitabinetenofovir alafenamide oncedaily single tablet regimen treatment hiv concerta methylphenidate hcl extendedrelease tablets cii treatment attention deficit hyperactivity disorder invega sustenna xeplion paliperidone palmitate treatment schizophrenia schizoaffective disorder adults invega trinza trevicta paliperidone palmitate treatment schizophrenia patients adequately treated invega sustenna least four months risperdal consta risperidone longacting injection treatment schizophrenia maintenance treatment bipolar disorder adults zytiga abiraterone acetate treatment patients prostate cancer erleada apalutamide nextgeneration androgen receptor inhibitor treatment patients prostate cancer imbruvica ibrutinib treatment certain bcell malignancies blood cancers chronic graft versus host disease darzalex daratumumab treatment multiple myeloma darzalex faspro daratumumab hyaluronidase fihj treatment multiple myeloma light chain al amyloidosis procrit eprex epoetin alfa treatment chemotherapyinduced anemia patients chronic kidney disease xarelto rivaroxaban oral anticoagulant prevention deep vein thrombosis dvt may lead pulmonary embolism pe patients undergoing hip knee replacement surgery reduce risk stroke systemic embolism patients nonvalvular atrial fibrillation treatment reduction risk recurrence dvt pe reduce risk major cardiovascular events patients coronary artery disease cad peripheral artery disease pad treatment secondary prevention thromboembolism pediatric patients thromboprophylaxis pediatric patients following fontan procedure invokana canagliflozin treatment adults type diabetes invokamet vokanamet canagliflozinmetformin hcl combination therapy fixed doses canagliflozin metformin hydrochloride treatment adults type diabetes invokamet xr canagliflozinmetformin hydrochloride extendedrelease oncedaily fixeddose combination therapy canagliflozin metformin hydrochloride extendedrelease treatment adults type diabetes opsumit macitentan monotherapy combination indicated longterm treatment pulmonary arterial hypertension pah uptravi selexipag approved oral intravenous selective ip receptor agonist targeting prostacyclin pathway pah many medicines developed collaboration strategic partners licensed companies maintain active lifecycle development programs medical devices medical devices segment includes broad range products used interventional solutions orthopaedics surgery vision fields medical devices interventional solutions include electrophysiology products biosense webster treat cardiovascular diseases neurovascular care cerenovus treats hemorrhagic ischemic stroke orthopaedics portfolio depuy synthes comprised products support hips knees trauma spine sports surgery portfolios include advanced general surgery offerings ethicon solutions focus breast aesthetics mentor ear nose throat acclarent procedures johnson johnson vision products acuvue brand disposable contact lenses ophthalmic products related cataract laser refractive surgery products distributed wholesalers hospitals retailers used predominantly professional fields physicians nurses hospitals eye care professionals clinics beginning fiscal first quarter medical devices segment referred medtech segment geographic areas johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products healthcare field company conducts business virtually countries world primary focus products related human health wellbeing products made sold international business include many described segments business consumer health pharmaceutical medical devices however principal markets products methods distribution international business vary country culture products sold international business include developed us subsidiaries abroad investments activities countries outside us subject higher risks comparable us activities investment commercial climate may influenced financial instability international economies restrictive economic policies political legal system uncertainties raw materials raw materials essential company 's business generally readily available multiple sources exceptions temporary unavailability raw materials would likely material adverse effect financial results company patents company 's subsidiaries made practice obtaining patent protection products processes possible licensed significant number patents us countries relating products product uses formulations manufacturing processes aggregate believed material importance company operation businesses companys subsidiaries face patent challenges thirdparties including challenges seeking manufacture market generic biosimilar versions company 's key pharmaceutical products prior expiration applicable patents covering products significant legal proceedings claims involving company 's patent intellectual property described note legal proceedings intellectual property notes consolidated financial statements included item report sales companys largest product stelara ustekinumab accounted approximately company 's total revenues fiscal accordingly patents related product believed material company janssen biotech inc whollyowned subsidiary johnson johnson owns patents specifically related stelara latest expiring united states composition matter patent expires latest expiring european composition matter patent expires sales companys second largest product collectively darzalex daratumumab darzalex faspro daratumumab hyaluronidasefihj accounted approximately company 's total revenues fiscal accordingly patents related product believed material company genmab owns two patent families related darzalex janssen biotech inc exclusive license patent families two patent families expire united states latest expiring licensed european patent expires janssen biotech inc owns separate patent portfolio related darzalex faspro trademarks companys subsidiaries made practice selling products trademarks obtaining protection trademarks available means trademarks protected registration us countries products marketed company considers trademarks aggregate material importance operation businesses seasonality worldwide sales reflect significant degree seasonality however spending heavier fourth quarter year quarters reflects increased spending decisions principally advertising research development activity competition product lines company 's subsidiaries compete companies locally globally competition exists product lines without regard number size competing companies involved competition research internally externally sourced involving development improvement new existing products processes particularly significant development new innovative products well protecting underlying intellectual property companys product portfolio important company 's success areas business competitive environment requires substantial investments continuing research addition development maintenance customer demand companys consumer products involve significant expenditures advertising promotion environment company subject variety us international environmental protection measures company believes operations comply material respects applicable environmental laws regulations companys compliance requirements expected material effect upon capital expenditures cash flows earnings competitive position regulation companys businesses subject varying degrees governmental regulation countries operations conducted general trend toward increasingly stringent regulation enforcement company subject costly complex us foreign laws governmental regulations adverse regulatory action may materially adversely affect company 's financial condition business operations us drug device cosmetic industries long subject regulation various federal state agencies primarily product safety efficacy manufacturing advertising labeling safety reporting exercise broad regulatory powers us food drug administration us fda continues result increases amounts testing documentation required us fda approval new drugs devices corresponding increase expense product introduction similar trends also evident major markets outside us new medical device regulatory framework new privacy regulations europe countries examples increased regulation regulatory agencies whose purview company operates administrative powers may subject actions product withdrawals recalls seizure products civil criminal sanctions cases companys subsidiaries may deem advisable initiate product recalls us fda regulatory agencies around globe also increasing enforcement activities us fdawere conclude compliance applicable laws regulations drugs medical devices ineffective pose unreasonable health risk us fda could ban products detain seize adulterated misbranded products order recall repair replacement refund products refuse grant pending applications marketing authorization require certificates foreign governments exports andor require us notify health professionals others products present unreasonable risks substantial harm public health us fda may also assess civil criminal penalties us officers employees impose operating restrictions companywide basis enjoin andor restrain certain conduct resulting violations applicable law us fda may also recommend prosecution us department justice adverse regulatory action depending magnitude may restrict us effectively marketing selling products limit ability obtain future clearances approvals could result substantial modification business practices operations equivalent enforcement mechanisms exist different countries conduct business costs human healthcare continue subject study investigation regulation governmental agencies legislative bodies around world us attention focused states regulatory agencies congress drug prices profits programs encourage doctors write prescriptions particular drugs recommend use purchase particular medical devices laws regulations enacted require adherence strict compliance standards prevent fraud abuse healthcare industry increased focus interactions financial relationships healthcare companies healthcare providers various transparency laws regulations require disclosures payments transfers value made physicians teaching hospitals beginning disclosures certain nonphysician practitioners federal foreign laws governing international business practices require strict compliance antibribery standards certain prohibitions respect payments foreign government official payers become potent force market place increased attention paid drug medical device pricing appropriate drug medical device utilization quality costs healthcare generally us government actors continue efforts repeal modify invalidate provisions patient protection affordable care act aca passed example federal legislation repealed acas individual mandate tax penalty well tax generous employersponsored healthcare plans center medicare medicaid services cms began permitting states impose work requirements persons covered medicaid expansion plans certain federal subsidies insurers ended certain shortterm insurance plans offering full array aca benefits allowed extend duration changes challenged us courts longterm impact remains uncertain aca also subject judicial challenge november us supreme court heard argument texas v azar challenges constitutionality aca pending resolution litigation aca individual mandate buy health insurance remains effect us government also continues propose implement changes medicare part benefit including size manufacturer discounts coverage gap catastrophic phases benefit number additional bills pending congress healthcare reform proposals state level would affect drug pricing medicare medicaid programs changing federal landscape positive negative impacts us healthcare industry much remaining uncertain various provisions federal law potential modification repeal laws ultimately affect industry addition business practices healthcare industry come increased scrutiny particularly us government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties company relies global supply chains production distribution processes complex subject increasing regulatory requirements may faced unexpected changes resulting covid pandemic brexit may affect sourcing supply pricing materials used company 's products processes also subject complex lengthy regulatory approvals global regulatory landscape also subject change covid pandemic continues affect us global economies us fda health authorities shifted resources priorities meet many challenges presented pandemic pandemicrelated disruptions could negatively impact processing regulatory submissions slow agency review times necessary approval clearance new drugs devices duration severity covid pandemic unpredictable difficult assess employees human capital management january january number employees approximately employees fulltime equivalent fte positions employee defined individual working fulltime parttime excluding fixed term employees interns coop employees employee data may include full population recently acquired companies individuals longterm disability excluded contingent workers contractors subcontractors also excluded fte represents total number fulltime equivalent positions reflect total number individual employees work parttime strategy company believes employees critical continued success essential element longterm strategy management responsible ensuring policies processes reflect reinforce company 's desired corporate culture including policies processes related strategy risk management ethics compliance companys human capital management strategy built three fundamental focus areas attracting recruiting best talent developing retaining talent empowering inspiring talent underpinning focus areas ongoing efforts cultivate foster culture built diversity equity inclusion dei innovation health wellbeing safety company 's employees encouraged succeed professionally personally helping company achieve business goals culture employee engagement johnson johnson employees guided credo sets forth company 's responsibilities patients consumers customers healthcare professionals employees communities shareholders employees worldwide guided companys code business conduct sets basic requirements business conduct serves foundation company policies procedures guidelines provide additional guidance expected employee behaviors every market operates company conducts global surveys offer employees ability provide feedback valuable insight help address potential human resources risks identify opportunities improve global employees across countries participated voice survey offered languages growth development continue lead changing healthcare landscape crucial company continue attract retaintop talent company believes employees must equipped right knowledge skills provided opportunities grow develop careers accordingly professional development programs educational resources available employees company 's objective foster learning culture helps shape persons unique career path creating robust pipeline talent deliver companys longterm strategies furtherance objective company deploys global approach ensure development everyone regardless career journey employees manager job categories took advantage career opportunities moving across functions country business segment lines including upward promotion lateral transfer excluding employees research development organizations company 's voluntary turnover rate diversity equity inclusion dei company committed workplace diversity cultivating fostering advancing culture equity inclusion enabling employees perform best fundamental company 's continued success companys dei vision change world company 's dei strategy focuses three pillars reflect strategic priorities identified enable company address challenges opportunities presented evolving understanding diversity accelerate companys efforts advance culture inclusion innovation build diverse workforce future enhance business results reputation company 's dei strategy guided internal external insights global best practices continual employee feedback remind company diversity changes location inclusion everywhere compensation benefits part company 's total rewards philosophy company offers competitive compensation benefits attract retain top talent company committed fairness equitable treatment compensation benefits employees levels company observes legal minimum wage provisions exceeds possible company 's total rewards offerings include array programs support employees ' financial physical mental wellbeing including annual performance incentive opportunities pension retirement savings programs health welfare benefits paid time leave programs flexible work schedules employee assistance programs health wellness safety companys investment employee health wellbeing safety built conviction advancing health humanity starts advancing health employees right awareness focus practices tools company ensures employees around world well temporary contractors visitors company 's sites work safely company continuously expanded health wellbeing programs throughout company across globe incorporating new thinking technologies keep offerings bestinclass help employees achieve personal health goals programs practices company advances total healthphysical mental emotional financialhelp ensure employee health protection emerging health risks safety covid pandemic response protecting supporting employees covid pandemic continues top priority approach includes keeping employees informed local covid transmission rates corresponding risk levels promoting health safety employees workplace robust layers protection enhanced cleaning access cleaning supplies personal protective equipment supporting employees pay continuity benefits wellbeing tools recognizing extraordinary employee contributions work communities recognition new way working initiated jj flex hybrid model empowers officebased employees find right productivity balance inperson remote work model allows work happen seamlessly across variety workplaces enabled array enhanced collaboration tools technology optimize productivity connection jj flex rolled fourth quarter globally continue deployment protocol requirements related covid pandemic allow company evaluating flexible work strategies onsite workforce virtual onboarding training help employees balance personal professional lives also continued enhance benefits offerings access wellness tools onsite vaccine clinics mental health support resources delivery athome testing kits addition covid vaccines broadly distributed administered including one developed johnson johnson adopted policies us puerto rico certain countries require proof vaccination johnson johnson employees contingent workers order return sites permitted local law regulation us puerto rico requirement took effect october processes established granting accommodations medical religious needs select manufacturing distributionemployees contractors us puerto rico well certain additional countries adopting similar policies early available information companys main corporate website address wwwjnjcom companys sec filings also available companys website wwwinvestorjnjcomseccfm soon reasonably practicable electronically filed furnished sec sec filings also available secs website wwwsecgov investors public note company also announces information wwwfactsaboutourprescriptionopioidscom wwwfactsabouttalccom wwwltlmanagementinformationcom use websites communicate investors public products litigation matters possible information post websites could deemed material information therefore encourage investors others interested company review information posted websites conjunction wwwjnjcom company 's sec filings press releases public conference calls webcasts addition amended restated certificate incorporation bylaws written charters audit committee compensation benefits committee nominating corporate governance committee regulatory compliance committee science technology sustainability committee special committee board directors companys principles corporate governance code business conduct employees code business conduct ethics members board directors executive officers corporate governance materials available wwwinvestorjnjcomgovcfm company 's website provided without charge shareholder submitting written request provided information wwwjnjcom wwwfactsaboutourprescriptionopioidscom wwwfactsabouttalccom wwwltlmanagementinformationcom deemed part report incorporated filings company makes sec item risk factors investment companys common stock debt securities involves risks uncertainties company seeks identify manage mitigate risks business uncertainties risks difficult predict many outside companys control therefore eliminated addition information report companys filings sec investors consider carefully factors set forth investors aware possible predict identify factors following meant complete discussion potential risks uncertainties known unknown risks uncertainties materialize companys business results operations financial condition could adversely affected potentially material way risks related business industry operations companys businesses operate highly competitive product markets competitive pressures could adversely affect companys earnings company faces substantial competition three operating segments geographic markets companys businesses compete companies sizes basis costeffectiveness technological innovations intellectual property rights product performance real perceived product advantages pricing availability rate reimbursement company also competes market participants securing rights acquisitions collaborations licensing agreements third parties competition rights product candidates technologies may result significant investment acquisition costs onerous agreement terms company competitors development effective less costly products andor ability secure patent intellectual property rights successfully market products ahead company could negatively impact sales companys existing products well ability bring new products market despite significant prior investment related product development companys pharmaceutical businesses loss patent exclusivity product often followed substantial reduction sales competitors gain regulatory approval generic competing products enter market similar competition triggered loss exclusivity biological product companys medical devices businesses technological innovation product quality reputation customer service especially important competitiveness development companies new improved products processes technologies could threaten make companys products technologies less desirable less economical obsolete companys consumer health businesses face intense competition branded products retailers privatelabel brands company fails sufficiently differentiate market brand name consumer products could adversely affect revenues profitability products interruptions delays manufacturing operations could adversely affect companys business sales reputation companys manufacture products requires timely delivery sufficient amounts complex highquality components materials companys subsidiaries operate manufacturing facilities well sourcing thousands suppliers around world company past may future face unanticipated interruptions delays manufacturing internal external supply chain manufacturing disruptions occur many reasons including regulatory action production quality deviations safety issues labor disputes labor shortages sitespecific incidents fires natural disasters hurricanes severe weather events raw material shortages political unrest terrorist attacks epidemics pandemics delays difficulties manufacturing result product shortages declines sales reputational impact well significant remediation related costs associated addressing shortage company relies third parties manufacture certain products failure loss thirdparty manufacturer could result delays increased costs may adversely affect business company relies third parties manufacture certain products depend thirdparty manufacturers allocate us portion manufacturing capacity sufficient meet needs produce products acceptable quality acceptable manufacturing yields deliver products us timely basis acceptable prices however guarantee thirdparty manufacturers able meet nearterm longterm manufacturing requirements could result lost sales adverse effect business risks associated reliance third parties manufacture products include reliance third party regulatory compliance quality assurance misappropriation companys intellectual property limited ability manageour inventory possible breach manufacturing agreement third party possible termination nonrenewal manufacturing agreement third party time costly inconvenient us moreover thirdparty manufacturers suffers damage facilities loses benefits material agreements experiences power outages encounters financial difficulties unable secure necessary raw materials suppliers suffers reduction efficiency company may experience significant business disruption event disruption company would need seek source qualified thirdparty manufacturers likely resulting delays increased costs could affect business adversely counterfeit versions products could harm patients negative impact revenues earnings reputation business industry continues challenged vulnerability distribution channels illegal counterfeiting presence counterfeit products growing number markets internet third parties may illegally distribute sell counterfeit versions products meet rigorous manufacturing testing standards distributors patients counterfeit products may visually indistinguishable authentic version counterfeit medicines pose risk patient health safety conditions manufactured often unregulated unlicensed uninspected unsanitary sites well lack regulation contents industrys failure mitigate threat counterfeit medicines could adversely impact business reputation impacting patient confidence authentic products potentially resulting lost sales product recalls increased threat litigation addition diversion products authorized market channels may result reduced revenues negatively affect profitability covid pandemic adversely impacted certain aspects companys business could cause disruptions future impact companys business results operations financial condition subject risks associated global health crises epidemics pandemics including global outbreak coronavirus variants covid covid pandemic adversely impacted expected continue adversely impact certain aspects companys business results operations financial condition including lower sales reduced customer demand usage certain products spread covid caused company modify business practices including instituting remote work many companys employees company may take actions may required government authorities company determines best interests patients customers employees business partners company continues monitor situation robust business continuity plans place across global supply chain network help mitigate impact covid efforts may completely prevent business adversely affected future impacts remain uncertain us countries begun begin reopen economies extent covid impact companys future operations depend many factors predicted confidence including duration outbreak impact variants resurgence covid could result imposition new mandates prolonged restrictive measures implemented order control spread disease continued global spread covid could adversely impact companys operations including among things manufacturing operations supply chain including thirdparty suppliers sales marketing clinical trial operations factors could adversely affect companys business financial results global economic conditions generally also face uncertainties related covid vaccine including uncertainties related risk continued development programs may successful commercially viable receive approval regulatory authorities risks associated clinical trial realworld data including analyses efficacy safety durability risk data subject differing interpretations assessments including peer reviewpublication process scientific community generally national immunization technical advisory groups nitags regulatory authorities disruptions relationships us thirdparty suppliers external manufacturers risk companies may produce superior competitive products risk demand products may develop may longer exist risks related availability raw materials manufacture products risk may able recoup costs associated rd manufacturing efforts risks associated changes way approach provide additional research funding potential drug development related covid risk may able create scale manufacturing capacity timely basis may continue experience manufacturing delays manufacturing site activated access logistics supply channels commensurate global demand potential approved vaccine product candidate would negatively impact ability supply estimated numbers doses vaccine within projected time periods indicated challenges risks associated pace vaccine development program pricing access challenges products including us addition extent covid pandemic adversely affects business financial results may also theeffect heightening many risks described risk factors section incorporated reference herein ncluding risks relating companys effective tax rate result changes consumption well changes laws relating supply companys products given developments concerning covid pandemic constantly evolving additional impacts risks may arise including litigation presently known company risks related government regulation legal proceedings global sales companys pharmaceutical medical devices segments may negatively impacted healthcare reforms increasing pricing pressures sales companys pharmaceutical medical devices products significantly affected reimbursements thirdparty payers government healthcare programs private insurance plans managed care organizations part various efforts contain healthcare costs payers putting downward pressure prices products reimbursed us increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries part due continued consolidation among healthcare providers could result pricing pressures addition increased political scrutiny could result additional pricing pressures outside us numerous major markets including eu united kingdom japan china pervasive government involvement funding healthcare regard directly indirectly impose price controls limit access reimbursement companys products reduce value intellectual property protection company subject significant legal proceedings result significant expenses fines reputational damage ordinary course business johnson johnson subsidiaries subject numerous claims lawsuits involving various issues product liability patent disputes claims product sales marketing pricing practices violate various antitrust unfair trade practices andor consumer protection laws companys significant legal proceedings described note legal proceedings notes consolidated financial statements included item report litigation general securities derivative action class action multidistrict litigation particular expensive disruptive matters may include thousands plaintiffs may involve parties seeking large andor indeterminate amounts including punitive exemplary damages may remain unresolved several years example company defendant numerous lawsuits arising use body powders containing talc primarily johnsons baby powder companys sale manufacturing marketing opioids company believes substantial defenses matters feasible predict ultimate outcome litigation company could future required pay significant amounts result settlements judgments matters potentially excess accruals including matters company could held jointly severally liable among defendants resolution increase accruals one matters reporting period could material adverse effect companys results operations cash flows period company purchase thirdparty product liability insurance however company utilizes wholly owned captive insurance company subject certain limits product reliability safety effectiveness concerns significant negative impacts sales results operations lead litigation cause reputational damage concerns product safety whether raised internally litigants regulators consumer advocates whether based scientific evidence result safety alerts product recalls governmental investigations regulatory action part us food drug administration counterpart countries private claims lawsuits payment fines settlements declining sales reputational damage circumstances also result damage brand image brand equity consumer trust companys products product recalls past could future prompt government investigations inspections shutdown manufacturing facilities continued product shortages related sales declines significant remediation costs reputational damage possible civil penalties criminal prosecution company faces significant regulatory scrutiny imposes significant compliance costs exposes company government investigations legal actions penalties like companies healthcare industry company subject extensive regulation investigations legal action national state local government agencies us countries operates regulatory issues regarding compliance current good manufacturing practices cgmp comparable quality regulations foreign countries manufacturers drugs devices consumer products lead fines penalties product recalls product shortages interruptions production delays new product approvals litigation addition marketing pricing sale companys products subject regulation investigations legal actions including federal food drug cosmetic act medicaid rebate program federal state false claims acts state unfair trade practices acts consumer protection laws scrutiny healthcare industry business practices government agencies state attorneys general us resulting investigations prosecutions carry risk significant civil criminal penalties including limited debarment participation government healthcare programs debarment could materialadverse effect companys business results operations significant current investigations litigation brought government agencies described note legal proceedingsgovernment proceedings notes consolidated financial statements included item report changes tax laws exposures additional tax liabilities could negatively impact companys operating results changes tax laws regulations around world including us led organization economic cooperation development could negatively impact companys effective tax rate results operations change statutory tax rate certain international tax provisions country would result revaluation companys deferred tax assets liabilities related particular jurisdiction period new tax law enacted change would result expense benefit recorded companys consolidated statement earnings company closely monitors proposals arise countries operates changes tax laws regulations may occur time related expense benefit recorded may material fiscal quarter year law change enacted see note income taxes notes consolidated financial statements included item report additional information company conducts business files tax returns numerous countries addressing tax audits disputes many tax authorities connection various government initiatives companies required disclose information tax authorities operations around world may lead greater audit scrutiny profits earned countries company regularly assesses likely outcomes tax audits disputes determine appropriateness tax reserves however tax authority could take position tax treatment contrary companys expectations could result tax liabilities excess reserves risks related intellectual property company faces increased challenges intellectual property rights central business company owns licenses significant number patents proprietary rights relating products manufacturing processes rights essential companys businesses materially important companys results operations public policy within outside us become increasingly unfavorable toward intellectual property rights company certain obtain adequate patent protection new products technologies united states important markets protections granted last long originally anticipated competitors routinely challenge validity extent companys owned licensed patents proprietary rights litigation interferences oppositions proceedings inter partes review ipr proceedings united states patent trademark office uspto proceedings absorb resources protracted well unpredictable addition challenges companys products infringe patents third parties could result injunction andor need pay past damages future royalties adversely affect competitive position sales products question company faced increasing patent challenges third parties seeking manufacture market generic biosimilar versions companys key pharmaceutical products prior expiration applicable patents covering products us manufacturers generic versions innovative human pharmaceutical products may challenge validity claim noninfringement innovator products abbreviated new drug application anda process us fda related anda litigation biologics price competition innovation act bpcia enacted created new regulatory pathway approval us fda biosimilar alternatives innovator developed biological products also created mechanisms biosimilar applicants challenge patents innovator biologics ipr process uspto also used competitors challenge patents asserted litigation event company successful defending patents challenges upon atrisk launch generic biosimilar firm product company lose major portion revenues referenced product short period time current legal proceedings involving companys patents intellectual property rights described note legal proceedingsintellectual property notes consolidated financial statements included item report risks related product development regulatory approval commercializationsignificant challenges delays companys innovation development new products technologies indications could adverse impact companys longterm success companys continued growth success depends ability innovate develop new differentiated products services address evolving healthcare needs patients providers consumers development successful products technologies also necessary offset revenue losses companys existing products lose market share due various factors competition loss patent exclusivity new products introduced within past five years accounted approximately sales company certain whether able develop license otherwise acquire companies products technologies whether particular product candidates granted regulatory approval approved whether products commercially successful company pursues product development internal research development well collaborations acquisitions joint ventures licensing arrangements third parties contexts developing new products particularly pharmaceutical biotechnology products medical devices requires significant investment resources many years biopharmaceutical research development programs result commercially viable products process depends many factors including ability discern patients healthcare providers future needs develop promising new compounds strategies technologies achieve successful clinical trial results secure effective intellectual property protection obtain regulatory approvals timely basis reach market successfully differentiate companys products competing products approaches treatment new products enhancements existing products may accepted quickly significantly marketplace due product price competition changes customer preferences healthcare purchasing patterns resistance healthcare providers uncertainty thirdparty reimbursement even following initial regulatory approval success product adversely impacted safety efficacy findings larger realworld patient populations well market entry competitive products risks related financial economic market conditions company faces variety financial economic legal social political risks associated conducting business internationally companys extensive operations business activity throughout world accompanied certain financial economic legal social political risks including listed foreign currency exchange fiscal approximately companys sales occurred outside us approximately europe western hemisphere excluding us asiapacific africa region changes nonus currencies relative us dollar impact companys revenues expenses company uses financial instruments mitigate impact fluctuations currency exchange rates cash flows unhedged exposures continue subject currency fluctuations addition weakening strengthening us dollar may result significant favorable unfavorable translation effects operating results companys nonus business activity translated us dollars inflation currency devaluation risks company faces challenges maintaining profitability operations economies experiencing high inflation rates company accounted operations argentina venezuela highly inflationary prior threeyear cumulative inflation rate surpassed company strives maintain profit margins areas cost reduction programs productivity improvements periodic price increases might experience operating losses result continued inflation addition impact currency devaluations countries experiencing high inflation rates significant currency exchange fluctuations could negatively impact companys operating results illegal importation pharmaceutical products illegal importation pharmaceutical products countries government price controls market dynamics result lower prices may adversely affect companys sales profitability us countries company operates exception limited quantities prescription drugs personal use foreign imports pharmaceutical products illegal current us law however volume illegal imports continues rise ability patients customers obtain lowerpriced imports grown significantly antibribery regulations company subject various federal foreign laws govern international business practices respect payments government officials laws include us foreign corrupt practices act fcpa prohibits us publicly traded companies promising offering giving anything value foreign officials corrupt intent influencing foreign official purpose helping company obtain retainbusiness gain improper advantage companys business heavily regulated therefore involves significant interaction foreign officials also many countries outside us healthcare providers prescribe human pharmaceuticals employed government purchasers human pharmaceuticals government entities therefore companys interactions prescribers purchasers subject regulation fcpa addition us application enforcement fcpa various jurisdictions company operates laws regulations including uk bribery act aimed preventing penalizing corrupt anticompetitive behavior enforcement activities laws could subject company additional administrative legal proceedings actions could include claims civil penalties criminal sanctions administrative remedies including exclusion healthcare programs financial economic legal social political risks risks inherent conducting business globally include local regional economic environments policies markets serve including interest rates monetary policy inflation economic growth recession commodity prices currency controls limitations ability expatriate cash protective economic policies taken governments trade protection measures importexport licensing requirements compliance local regulations laws including countries regulatory requirements restricting companys ability manufacture sell products relevant market diminished protection intellectual property contractual rights certain jurisdictions potential nationalization expropriation companys foreign assets political social upheavals economic instability repression human rights issues geopolitical events including natural disasters disruptions markets due war armed conflict terrorism epidemics pandemics failure maintain satisfactory credit rating could adversely affect liquidity capital position borrowing costs access capital markets currently maintain investment grade credit ratings moodys investors service standard poors ratings services rating agencies routinely evaluate us ratings longterm shortterm debt based number factors downgrade credit ratings credit rating agency whether result actions factors beyond control increase cost borrowing indebtedness may incur reduce market capacity commercial paper require posting additional collateral derivative contracts assurance able maintain credit ratings additional actual anticipated changes downgrades credit ratings including announcement ratings review downgrade may negative impact liquidity capital position access capital markets risks related planned separation consumer health business planned separation companys consumer health business may completed terms timeline currently contemplated may achieve expected results november company announced intention separate companys consumer health business intention create new publicly traded company planned separation intended qualify taxfree transaction us federal income tax purposes company targeting completion planned separation months initial announcement completion planned separation subject satisfaction certain conditions including among others consultations works councils employee representative bodies required final approval companys board directors receipt favorable opinion internal revenue service irs ruling respect taxfree nature transaction receipt regulatory approvals assurance regarding ultimate timing planned separation separation completed unanticipated developments could delay prevent otherwise adversely affect planned separation including limited disruptions general financial market conditions potential problems delays obtaining various regulatory tax approvals clearances costs complete planned separation significant addition company may unable achieve strategic financial benefits expects achieve planned separation companys consumer health business company incur significant expenses connection planned separation addition company may able achieve full strategic financial benefits expected result planned separation anticipated benefits planned separation based number assumptions may prove incorrectfollowing planned separation price shares companys common stock may fluctuate significantly company predict effect planned separation trading price shares common stock market value shares common stock may less equal greater market value shares common stock prior planned separation addition price companys common stock may volatile around time planned separation planned separation could result substantial tax liability company intends obtain opinion us tax advisors ruling irs taxfree nature planned separation us internal revenue code amended opinion ruling based among things various factual assumptions representations company new consumer health company make regarding past future conduct companies respective businesses matters assumptions representations become inaccurate incomplete reliance opinion ruling may jeopardized subsequent planned separation determined transaction qualify taxfree treatment us federal income tax purposes resulting tax liability company shareholders could substantial planned separation may also qualify taxfree treatment countries around world result may trigger substantial tax liability company risks business depends ability recruit retain talented highly skilled employees diverse workforce continued growth requires us recruit retain talented employees representing diverse backgrounds experiences skill sets market highly skilled workers leaders industry extremely competitive ability compete depends ability hire develop motivate highly skilled personnel areas organization maintaining brand reputation well diverse equitable inclusive work environment enables us attract top talent less successful recruiting efforts retain highly skilled workers key leaders ability develop deliver successful products services may adversely affected addition effective succession planning important longterm success unsuccessful implementation succession plans failure ensure effective transfer knowledge smooth transitions involving key employees could adversely affect business financial condition results operations climate change legal regulatory market measures address climate change may negatively affect business results operations climate change resulting increased concentrations carbon dioxide greenhouse gases atmosphere could present risks operations including adverse impact global temperatures weather patterns frequency severity extreme weather natural disasters natural disasters extreme weather conditions hurricane tornado earthquake wildfire flooding may pose physical risks facilities disrupt operation supply chain impacts changing climate water resources may result water scarcity limiting ability access sufficient highquality water certain locations may increase operational costs concern climate change may also result new additional legal regulatory requirements designed reduce greenhouse gas emissions andor mitigate effects climate change environment laws regulations stringent current legal regulatory obligations may experience disruption increase costs associated sourcing manufacturing distribution products may adversely affect business results operations financial condition impacts climate change influence customer preferences failure provide climatefriendly products could potentially result loss market share information security incident including cybersecurity breach could negative impact companys business reputation meet business objectives company relies internal information technology systems networks third parties vendors process store sensitive data including confidential research business plans financial information intellectual property personal data may subject legal protection ensure continuity companys supply chain extensive information security cybersecurity threats affect companies globally pose risk security availability systems networks confidentiality integrity availability companys sensitive data company continually assesses threats makes investments increase internal protection detection response capabilities well ensure companys thirdparty providers required capabilitiesand controls address risk date company experienced material impact business operations resulting information cybersecurity attacks however frequently changing attack techniques along increased volume sophistication attacks potential company adversely impacted impact could result reputational competitive operational business harm well financial costs regulatory action company maintains cybersecurity insurance event information security cyber incident however coverage may sufficient cover financial legal business reputational losses breach privacy laws unauthorized access loss misuse personal data could negative impact companys business reputation company subject privacy data protection laws across globe impose broad compliance obligations collection use storage access transfer protection personal data breach requirements could result substantial fines penalties private right actions claims damage reputation business new privacy laws expected territories together greater privacy enforcement governmental authorities globally particularly data localization requirements international data flows company established privacy compliance programs controls businesses worldwide required comply many technology datadriven initiatives prioritized across company involving multiple vendors third parties potential risks controls imposed cross border data flows unauthorized access loss personal data internal external threats could impact business operations research activities item b unresolved staff comments applicable item properties company 's subsidiaries operate manufacturing facilities occupying approximately million square feet floor space manufacturing facilities used industry segments companys business approximately follows square feet segment thousands consumer health pharmaceutical medical devices worldwide total within us four facilities used consumer health segment five pharmaceutical segment medical devices segment outside us facilities used consumer health segment pharmaceutical segment medical devices segment locations manufacturing facilities major geographic areas world follows number square feet geographic area facilities thousands united states europe western hemisphere excluding us africa asia pacific worldwide total addition manufacturing facilities discussed company maintains numerous office warehouse facilities throughout world company 's subsidiaries generally seek rather lease manufacturing facilities although principally nonus locations leased office warehouse facilities often leased company also engages contract manufacturers company committed maintaining properties good operating condition mcneilppc inc johnson johnson consumer inc mcneilppc operated consent decree signed us fda governed certain mcneil consumer healthcare manufacturing operations required mcneilppc remediate facilities operates lancaster pennsylvania fort washington pennsylvania las piedras puerto rico consent decree following us fda inspections mcneilppc received notifications us fda three manufacturing facilities conformity applicable laws regulations commercial production restarted consent decree receiving notice us fda compliance applicable laws regulations three facilities subject fiveyear audit period thirdparty cgmp expert thirdparty expert continued reassess sites various times us fda inspections facilities delayed due covid completed consent decree vacated july segment information additions property plant equipment contained note segments business geographic areas notes consolidated financial statements included item report item legal proceedings information called item incorporated herein reference information set forth note legal proceedings notes consolidated financial statements included item report item mine safety disclosures applicable executive officers registrant listed executive officers company family relationships executive officers arrangement understanding executive officer person pursuant executive officer selected annual meeting board directors executive officers elected board hold office one year respective successors elected qualified earlier resignation removal information regard directors company incorporated herein reference material captioned item election directors proxy statement name age position vanessa broadhurst member executive committee executive vice president global corporate affairs joaquin duato chief executive officer chairman executive committee b peter fasolo phd member executive committee executive vice president chief human resources officer c william n hait md ph member executive committee executive vice president chief external innovation medical safety global public health officer mathai mammen ph member executive committee executive vice president pharmaceuticals rd e ashley mcevoy member executive committee executive vice president worldwide chairman medical devices f thibaut mongon member executive committee executive vice president worldwide chairman consumer health g james swanson member executive committee executive vice president chief information officer h jennifer l taubert member executive committee executive vice president worldwide chairman pharmaceuticals michael h ullmann member executive committee executive vice president general counsel j kathryn e wengel member executive committee executive vice president chief global supply chain officer k joseph j wolk member executive committee executive vice president chief financial officer l ms v broadhurst joined company worldwide vice president anemia oncology supportive care went become vice president cardiovascular institutional franchise president janssen therapeutics becoming us president internal medicine held general manager roles amgen inflammation cardiovascular cardiovascular bone ms broadhurst rejoined johnson johnson us president cardiovascular metabolism member janssen americas leadership team role also provided operational oversight full portfolio janssen medicines puerto rico canada appointed company group chairman global commercial strategy organization ms broadhurst named executive vice president global corporate affairs member executive committee leading company 's global marketing communication design philanthropy functions b mr j duato became chief executive officer chairman executive committee joined board directors january joined company janssenfarmaceutica sa spain subsidiary company held executive positions increasing responsibility business sectors across multiple geographies functions named company group chairman pharmaceuticals named worldwide chairman pharmaceuticals mr duato became member executive committee named executive vice president worldwide chairman pharmaceuticals july mr duato promoted vice chairman executive committee provided strategic direction pharmaceutical consumer health sectors oversaw global supply chain information technology health wellness teams dual citizen spain united states mr duato 's international perspective global lens gives deep appreciation diverse thoughts opinions c dr p fasolo joined company worldwide vice president human resources medical devices segment subsequently served companys chief talent officer left johnson johnson join kohlberg kravis roberts co chief talent officer dr fasolo returned company vice president global human resources became member executive committee april named executive vice president chief human resources officer dr fasolo responsibility global talent recruiting diversity compensation benefits employee relations aspects human resources agenda company also serves boards human resources policy association tufts university save children named fellow national academy human resources dr w hait joined company senior vice president worldwide head oncology research served first global therapeutic area head oncology global head janssen research development global head johnson johnson global external innovation became executive vice president chief external innovation medical safety global public health officer member executive committee responsible leading external sourcing creation transformational innovation help johnson johnson achieve mission improve human health utilizing companys excellence pharmaceuticals medical devices consumer products also oversight global public health office chief medical officer e dr mammen joined company global head rd janssen pharmaceutical companies johnson johnson prior joining janssen june dr mammen senior vice president merck research laboratories responsible research areas cardiovascular metabolic renal diseases oncologylmmunooncology immunology prior merck led rd theravance company cofounded san francisco bay area based work harvard university named executive vice president pharmaceuticals rd member executive committee responsible team whose mission make transformational medicines unequivocal benefit patients worldwide working across wide range therapeutic areas biological pathways areas oncology cardiovascular metabolic disease retinal disease pulmonary hypertension immunology neuroscience infectious disease vaccines therapeutic areas fueled worldclass global functions discovery sciences manufacturing regulatory affairs development operations data science f ms mcevoy joined company assistant brand manager mcneil consumer health subsidiary company advancing positions increasing responsibilities appointed company group chairman vision care followed company group chairman consumer medical devices july ms mcevoy promoted executive vice president worldwide chairman medical devices became member executive committee ms mcevoy responsibility surgery orthopaedics interventional solutions eye health businesses across ethicon depuy synthes biosense webster johnson johnson vision g mr mongon joined company director marketing vision care group france subsequently held positions increasing responsibility transitioned pharmaceutical sector global commercial strategy leader neuroscience therapeutic area joined consumer health sector company group chairman asiapacific promoted executive vice president worldwide chairman consumer health became member executive committee mr mongon responsibility global development johnson johnsons health wellness products solutions beauty otc oral care baby care womens health wound care h mr j swanson rejoined company chief information officer johnson johnson bayer crop science served member executive leadership team cio head digitaltransformation mr swanson held positions increasing responsibility company including project manager director sr director vice president chief information officer mr swanson responsible enhancing johnson johnsons business impact shaping direction strategic use technology mr swanson executive vice president chief information officer joined executive committee effective january ms j l taubert joined company worldwide vice president held several executive positions increasing responsibility pharmaceutical sector appointed company group chairman north america pharmaceuticals became company group chairman americas pharmaceuticals july ms taubert promoted executive vice president worldwide chairman pharmaceuticals became member executive committee ms taubert responsible pharmaceutical sector globally including shaping companys strategy transformational medical innovation successfully bringing market critical new medicines significantly improve lives patients living cancer immunerelated diseases cardiovascular disease infectious diseases pulmonary hypertension serious mental illness j mr h ullmann joined company corporate attorney law department appointed corporate secretary served role time also held various management positions law department named general counsel medical devices diagnostics appointed vice president general counsel became member executive committee april mr ullmann named executive vice president general counsel mr ullmann worldwide responsibility legal government affairs policy global security aviation healthcare compliance global brand protection privacy k ms k e wengel joined company project engineer engineering supervisor janssen subsidiary company tenure company held variety strategic leadership executive positions across global enterprise roles within operations quality engineering new products information technology technical business functions ms wengel became first chief quality officer company promoted vice president johnson johnson supply chain july promoted executive vice president chief global supply chain officer became member executive committee ms wengel enterprisewide responsibilities supply chain quality compliance procurement engineering property services environmental health safety sustainability l mr j j wolk joined company finance manager business development orthomcneil subsidiary company years held variety senior leadership roles several segments functions across company 's subsidiaries pharmaceuticals medical devices supply chain served vice president finance chief financial officer janssen pharmaceutical companies johnson johnson mr wolk became vice president investor relations july appointed executive vice president chief financial officer became member executive committee mr wolk plays strategic role overall management company leads development execution company 's global longterm financial strategy part ii item market registrants common equity related stockholder matters issuer purchases equity securities february record holders common stock company additional information called item incorporated herein reference following sections report note common stock stock option plans stock compensation agreements notes consolidated financial statements included item item security ownership certain beneficial owners management related stockholder matters equity compensation plan information issuer purchases equity securities following table provides information respect common stock purchases company fiscal fourth quarter common stock purchases open market made part systematic plan meet needs companys compensation programs repurchases also include stockforstock option exercises settled fiscal fourth quarter total number maximum number shares units approximate dollar purchased part value shares total number publicly units may yet shares avg price announced plans purchased fiscal period purchased paid per share programs plans programs october october november november november january total fiscal fourth quarter company repurchased aggregate shares johnson johnson common stock openmarket transactions purchased openmarket transactions part systematic plan meet needs companys compensation programs item reserved item managements discussion analysis results operations financial condition organization business segments description company business segments johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products healthcare field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer health pharmaceutical medical devices consumer health segment includes broad range products used baby care oral care skin healthbeauty overthe counter pharmaceutical womens health wound care markets products marketed general public sold online ecommerce retail outlets distributors throughout world pharmaceutical segment focused six therapeutic areas including immunology infectious diseases neuroscience oncology pulmonary hypertension cardiovascular metabolic diseases products segment distributed directly retailers wholesalers distributors hospitals healthcare professionals prescription use medical devices segment includes broad range products used orthopaedic surgery interventional solutions cardiovascular neurovascular vision fields products distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals eye care professionals clinics executive committee johnson johnson principal management group responsible strategic operations allocation resources company committee oversees coordinates activities consumer health pharmaceutical medical devices business segments product lines company competes companies locally globally throughout world competition exists product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant development new innovative products well protecting underlying intellectual property company 's product portfolio important companys success areas business competitive environment requires substantial investments continuing research addition development maintenance customer demand companys consumer products involves significant expenditures advertising promotion managements objectives credo foundation companys purpose blend heart science ingenuity profoundly change trajectory health humanity company committed bringing full breadth depth ensure health people today future generations united around common ambition company poised fulfill purpose successfully meet demands rapidly evolving markets competes company broadly based human healthcare committed creating value developing accessible high quality innovative products services new products introduced within past five years accounted approximately sales billion invested research development reflecting managements commitment create lifeenhancing innovations create value partnerships profoundly change trajectory health humanity critical driver companys success diversity employees worldwide employees empowered inspired lead companys credo purpose guides allows every employee use companys reach size advance company 's purpose also lead agility urgency leveraging extensive resources across enterprise enables company innovate execute excellence ensures company remain focused addressing unmet needs society every day invest enduring impact ultimately delivering value patients consumers healthcare professionals employees communities shareholdersresults operations analysis consolidated sales discussion results operations financial condition pertaining fiscal years see companys annual report fiscal year ended january item management 's discussion analysis results operations financial condition worldwide sales increased billion compared increase sales changes consisted following sales increasedecrease due volume price currency total net impact acquisitions divestitures worldwide sales growth negative impact negative impact sales us companies billion billion represents increases sales international companies billion billion represents increase decrease fiveyear compound annual growth rates worldwide us international sales respectively tenyear compound annual growth rates worldwide us international sales respectively sales companies europe achieved growth compared prior year included operational growth positive currency impact sales companies western hemisphere excluding us achieved growth compared prior year included operational growth positive currency impact sales companies asiapacific africa region achieved growth compared prior year including operational growth positive currency impact company estimated inclusion rd week fiscal year results negatively impacted comparative sales growth approximately see note consolidated financial statements annual closing date details additional week added days sales also added full week 's worth operating costs therefore net earnings impact negligible company utilized three wholesalers distributing products three segments represented approximately total consolidated revenues company three wholesalers distributing products three segments represented approximately total consolidated revenuesnote values may rounded analysis sales business segments consumer health segment consumer health segment sales billion increase included operational growth positive currency impact us consumer health segment sales billion increase international sales billion increase included operational growth positive currency impact acquisitions divestitures net negative impact operational sales growth worldwide consumer health segment major consumer health franchise sales change vs dollars millions otc skin healthbeauty oral care baby care womens health wound careother total consumer health sales otc franchise sales billion increased compared prior year growth primarily attributable analgesics tylenol motrin digestive health hydration benefit offering orsl skin healthbeauty franchise sales billion increased compared prior year growth primarily due covid recovery strong performance neutrogena aveeno ecommerce acceleration partially offset divestiture dr cilabo sedona business asia pacific external supply constraints oral care franchise sales billion increased compared prior year market growth us along strong performance asia pacific region due successful brand building promotional campaigns positive impact currency offset negative impact floss divestiture us external supply constraints baby care franchise sales billion increased compared prior year growth driven aveeno asia pacific ecommerce strength innovation covid recovery womens health franchise sales billion increased compared prior year primarily driven covid market recovery favorable price strong brand building asia pacific partially offset disruptions europe due flooding wound careother franchise sales billion increased compared prior year growth due strong performance bandaid brand adhesive bandages us partially offset product discontinuations competitive pressures asia pacific november company announced intention separate companys consumer health business intention create new publicly traded company company targeting completion planned separation months initial announcement pharmaceutical segment pharmaceutical segment sales billion increase included operational growth positive currency impact us sales billion increase international sales billion increase included operational growth positive currency impact acquisitions divestitures net negative impact operational sales growth worldwide pharmaceutical segment adjustments previous sales reserve estimates approximately billion billion fiscal years respectively major pharmaceutical therapeutic area sales change vs dollars millions total immunology remicade simponi simponi aria stelara tremfya immunology total infectious diseases covid vaccine edurant rilpivirine prezista prezcobix rezolsta symtuza infectious diseases total neuroscience concerta methylphenidate invega sustenna xeplion invega trinza trevicta risperdal consta neuroscience total oncology darzalex erleada imbruvica zytiga abiraterone acetate oncology total pulmonary hypertension opsumit uptravi pulmonary hypertension total cardiovascular metabolism xarelto invokana invokamet procrit eprex total pharmaceutical sales certain prior year amounts reclassified conform current year presentation percentage greater meaningful inclusive velcade previously disclosed separately immunology products achieved sales billion representing increase compared prior year driven strong uptake stelara ustekinumab crohn 's disease ulcerative colitis strength tremfya guselkumab psoriasis uptake psoriatic arthritis partially offset lower sales remicade infliximab due biosimilar competition biosimilar versions remicade introduced united states certain markets outside united states additional competitors continue enter market continued infliximab biosimilar competition result reduction sales remicade latest expiring united states patent stelara ustekinumab expire september stelara ustekinumab us sales fiscal approximately billion expiration product patent loss market exclusivity likely result reduction sales infectious disease products achieved sales billion representing increase compared prior year growth primarily driven contribution covid vaccine partially offset lower sales prezista prezcobix rezolsta darunavircobicistat due increased competition loss exclusivity prezista certain countries outside us neuroscience products achieved sales billion representing increase compared prior year paliperidone longacting injectables growth driven sales invega sustenna xeplion paliperidone palmitate invega trinza trevicta new patient starts persistence well launch invega hafyera oncology products achieved sales billion representing increase compared prior year contributors growth strong sales darzalex daratumumab driven continued strong market growth share gains regions solid uptake subcutaneous formulation launched continued global launch uptake erleada apalutamide imbruvica ibrutinib growth primarily driven market continued share leadership growth imbruvica ibrutinib partially offset competitive pressures novel oral agents covid related market dynamics including delays new patient starts pulmonary hypertension products achieved sales billion representing increase compared prior year sales growth opsumit macitentan uptravi selexipag due continued share gains market growth cardiovascularmetabolismother products sales billion decline compared prior year decline primarily attributable lower sales invokana invokamet canagliflozin due share erosion procrit eprex epoetin alfa due biosimilar competition company advanced pipeline several regulatory submissions approvals new drugs additional indications existing drugs follows product name us eu us eu chemical name indication approval approval filing filing byannli maintenance treatment schizophrenia adults cabenuva rilpivirine hiv treatment use every two months cabotegravir covid vaccine covid emergency use covid vaccine covid emergency use booster shot darzalex subcutaneous sc formulation treatment newly daratumumab diagnosed systemic light chain amyloidosis gains additional approval pretreated multiple myeloma darzalex faspro combination carfilzomib dexamethasone daratumumab patients multiple myeloma first subsequent hyaluronidasefihj relapse invega hafyera first twiceyearly treatment adults paliperidone palmitate schizophrenia ponvory ponesimod treatment adults relapsing forms multiple sclerosis active disease defined clinical imaging features ponvory ponesimod oral treatment adults relapsing multiple sclerosis rybrevant treatment patients nonsmall cell lung cancer amivantamabvmjw egfr exon insertion mutations spravato rapid reduction depressive symptoms psychiatric esketamine emergency patients major depressive disorder stelara treatment pediatric patients juvenille psoriatic ustekinumab arthritis teclistamab treatment patients relapsed refractory multiple myeloma uptravi intravenous use adult patients pulmonary arterial selexipag hypertension pah xarelto help prevent treat blood clots pediatric patients rivaroxaban xarelto expanded peripheral artery disease pad indication rivaroxaban include patients lowerextremity revascularization ler medical devices segment medical devices segment sales billion increase included operational growth positive currency impact us sales billion increase compared prior year international sales billion increase compared prior year included operational growth positive currency impact net impact acquisitions divestitures medical devices segment worldwide operational sales growth negative primarily due divestiture advanced sterilization products asp company seen market recovery global procedural volumes medical devices segment compared prior year significant negative impacts covid procedural volume recovery primary driver sales earnings growth compared prior year major medical devices franchise sales change vs dollars millions surgery advanced general orthopaedics hips knees trauma spine sports vision contact lensesother surgical interventional solutions total medical devices sales surgery franchise achieved sales billion representing increase growth advanced surgery primarily driven endocutter biosurgery energy products attributable market recovery market expansion success new products offsetting competitive pressures us growth general surgery primarily driven market recovery continued strength suture portfolio partially offset impact asp divestiture prior year orthopaedics franchise achieved sales billion representing increase growth hips reflects market recovery combined continued strength portfolio including actis stem enabling technologies kincise velys hip navigation growth knees primarily driven procedure recovery new product introductions growth trauma driven global market recovery uptake new products growth spine sports primarily driven procedure recovery new product introductions vision franchise achieved sales billion representing increase contact lensesother operational growth due market recovery market share gains new products surgical vision operational growth primarily due market recovery uptake recently launched products interventional solutions franchise achieved sales billion increase growth electrophysiology stroke businesses driven market recovery success new products commercial strategies beginning fiscal first quarter medical devices segment referred medtech segment analysis consolidated earnings provision taxes income consolidated earnings provision taxes income billion billion years respectively percent sales consolidated earnings provision taxes income respectively dollars billions percentages chart percent total sales cost products sold selling marketing administrative expenses dollars billions percentages chart percent total sales cost products sold decreased percent sales driven nonrecurring prior year covid production related slowdowns related inventory impacts fixed cost deleveraging medical devices business fiscal favorable mix within pharmaceutical business well enterprise level higher percentage sales coming pharmaceutical business supply chain efficiencies consumer health segment intangible asset amortization expense included cost products sold billion fiscal years selling marketing administrative expenses decreased percent sales driven leveraging medical devices business resulting recovery sales prior years impact covid partially offset increased brand marketing expenses consumer health business research development expense research development expense segment business follows dollars millions amount sales amount sales consumer health pharmaceutical medical devices total research development expense percent increasedecrease prior year percent segment sales research development activities represent significant part company 's business expenditures relate processes discovering testing developing new products upfront payments developmental milestones improving existing products well ensuring product efficacy regulatory compliance prior launch company remains committed investing research development aim delivering high quality innovative products research development increased percent sales primarily driven general portfolio progression pharmaceutical business covid vaccine expenses net governmental reimbursements inprocess research development iprd fiscal year company recorded partial iprd charge billion primarily related expected development delays general surgery digital robotics platform ottava acquired auris health acquisition impairment charge calculated based revisions discounted cash flow valuation model reflecting delay first human procedures approximately two years initial acquisition model assumption second half company continue monitor remaining billion ottava platform intangible asset development program activities ongoing fiscal year company recorded iprd charge billion primarily related partial impairment due timing progression one digital surgery platforms acquired auris health acquisition january subsequent fiscal year additional information regarding efficacy became available led company decision terminate development bermekimab atopic dermatitis ad company recorded intangible asset impairment charge approximately billion related inprocess research development asset bermekimab jnj investigational drug treatment ad hidradenitis suppurativa hs impairment charge related ad indication nonrecognized subsequent event reflected first quarter financial statements company acquired rights bermekimab xbiotech inc fiscal year income expense net income expense net account company records gains losses related sale writedown certain investments equity securities held johnson johnson innovation jjdc inc jjdc unrealized gains losses investments income losses associated certain employee benefit programs gains losses divestitures certain transactional currency gains losses acquisitionrelated costs litigation accruals settlements well royalty income income expense net fiscal year favorable billion compared prior year primarily due following dollars billionsincomeexpense change litigation expense acquisition integration divestiture related gainslosses securities restructuring related employee benefit plan related total income expense net primarily related talc risperdal primarily related talc opioid litigation settlement p rimarily related divestiture gains two pharmaceutical brands outside us primarily driven contingent consideration reversal approximately billion related timing certain developmental milestones associated auris health acquisition includes consumer health separation costs billion costs future years expected significantly higher interest income expense fiscal year included net interest expense million compared million net interest expense fiscal year primarily due lower rates interest earned cash balances higher average debt balance partially offset benefit net investment hedging cash cash equivalents marketable securities totaled billion end averaged billion compared cash cash equivalents marketable securities total billion billion average cash balance total debt balance end billion average debt balance billion compared billion end average debt balance billion income tax segment income loss tax segment business follows income tax segment sales percent segment sales dollars millions consumer health pharmaceutical medical devices total less net expense allocated segments earnings provision taxes income see note consolidated financial statements details amounts allocated segments include interest income expense general corporate income expense consumer health segment consumer health segment income tax percent sales versus loss tax increase income tax percent sales primarily driven following litigation expense includes billion talc expenses includes billion talc expenses supply chain efficiencies partially offset increased brand marketing expenses commodity inflation pharmaceutical segment pharmaceutical segment income tax percent sales versus increase income tax percent sales primarily driven following divestiture gains billion related two pharmaceutical brands outside us fiscal litigation expense includes billion primarily related risperdal includes billion primarily related opioid litigation settlement partially offset research development investment covid vaccine net governmental reimbursements generalportfolio progression medical devices segment medical devices segment income tax percent sales versus increase income tax percent sales primarily driven following recovery prior year covid production related slow downs related inventory impacts overall expense leveraging resulting medical devices sales recovery litigation expense billion vs billion partially offset contingent consideration reversal approximately billion fiscal related timing certain developmental milestones associated auris health acquisition higher iprd charge billion billion related general surgery offering digital robotics ottava acquired auris health acquisition restructuring fiscal second quarter company announced plans implement actions across global supply chain intended enable company focus resources increase investments critical capabilities technologies solutions necessary manufacture supply product portfolio future enhance agility drive growth company expects supply chain actions include expanding use strategic collaborations bolstering initiatives reduce complexity improving costcompetitiveness enhancing capabilities optimizing network discussions regarding specific future actions ongoing subject relevant consultation requirements finalized total company expects actions generate approximately billion annual pretax cost savings substantially delivered end company expects record pretax restructuring charges approximately billion company estimates approximately cumulative pretax costs result cash outlays company recorded pretax charge billion included following lines consolidated statement earnings billion restructuring billion income expense billion cost products sold total project costs approximately billion recorded since restructuring announced program set completed end see note consolidated financial statements additional details related restructuring programs provision taxes income worldwide effective income tax rate discussion related fiscal provision taxes refer note consolidated financial statements liquidity capital resources liquidity cash flows cash cash equivalents billion end compared billion end primary sources uses cash contributed billion increase dollars billions q cash cash equivalents balance cash generated operating activities net cash used investing activities net cash used financing activities effect exchange rate rounding q cash cash equivalents balance addition company billion marketable securities end fiscal year billion end fiscal year see note consolidated financial statements additional details cash cash equivalents marketable securitiescash flow operations billion result dollars billions net earnings noncash expenses adjustments primarily depreciation amortization stockbased compensation asset writedowns partially offset deferred tax provision net gain sale assetsbusinesses credit losses accounts receivable allowances decrease current noncurrent liabilities increase accounts payable accrued liabilities increase accounts receivable inventories current noncurrent assets cash flow operations investing activities use billion cash primarily used dollars billions additions property plant equipment net purchases investments proceeds disposal assetsbusinesses net credit support agreements activity net acquisitions primarily licenses milestones rounding net cash used investing activities financing activities use billion cash primarily used dollars billions dividends shareholders repurchase common stock employee share programs net repayment short long term debt proceeds stock options exercisedemployee withholding tax stock awards net credit support agreements activity net rounding net cash used financing activities january company 's notes payable longterm debt excess cash cash equivalents marketable securities january net debt position billion compared prior year billion decrease net debt position due repayment debt increase cash cash equivalents marketable securities generating operations debt balance end billion compared billion considering recent market conditions ongoing covid crisis company evaluated operating cash flows liquidity profile foresee significant incremental risk company anticipates operating cash flows ability raise funds external sources borrowing capacity existing committed credit facilities access commercial paper markets continue provide sufficient resources fund operating needs including company 's approximate billion contractual supply commitments associated development covid vaccine opioid litigation settlement billion establishment billion trust talc related liabilities see note consolidated financial statements additional details addition company monitors global capital markets ongoing basis time time may raise capital market conditions favorable effective beginning fiscal us tax cuts job act currently requires company deduct us international research development expenditures tax purposes years instead current fiscal year result company expecting increase annual cash tax payments us treasury incremental billion beginning fiscal company concurrently record deferred tax benefit future amortization research development rd tax purposes therefore company expecting significant impact effective tax rate related change requirement expense rd incurred unchanged us gaap purposes impact pretax rd expense affected provision additionally result tax cuts jobs act tcja company access cash outside us significantly reduced cost fiscal third quarter accordance terms agreement associated acquisition actelion company 's undrawn credit facility idorsia terminated following table summarizes companys material contractual obligations aggregate maturities january satisfy obligations company intends use cash operations tax legislation interest dollars millions tcja debt obligations debt obligations total total tax matters see note consolidated financial statements table include activity related business combinations companys approximate billion contractual supply commitments associated development covid vaccine financing market risk company uses financial instruments manage impact foreign exchange rate changes cash flows accordingly company enters forward foreign exchange contracts protect value certain foreign currency assets liabilities hedge future foreign currency transactions primarily related product costs gains losses contracts offset gains losses underlying transactions appreciation us dollar january market rates would increase unrealized value companys forward contracts billion conversely depreciation us dollar january market rates would decrease unrealized value companys forward contracts billion either scenario gain loss forward contract would offset gain loss underlying transaction therefore would impact future anticipated earnings cash flows company hedges exposure fluctuations currency exchange rates effect certain assets liabilities foreign currency entering currency swap contracts change spread us foreign interest rates companys interest rate sensitive financial instruments would either increase decrease unrealized value companys swap contracts approximately billion either scenario maturity gain loss swap contract would offset gain loss underlying transaction therefore would impact future anticipated cash flows company enter financial instruments trading speculative purposes company policy entering contracts parties least investment grade credit rating counterparties contracts major financial institutions significant concentration exposure one counterparty management believes risk loss remote company entered credit support agreements csa certain derivative counterparties establishing collateral thresholds based respective credit ratings netting agreements see note consolidated financial statements additional details credit support agreements company invests fixed rate floating rate interest earning securities carry degree interest rate risk fair market value fixed rate securities may adversely impacted due rise interest rates floating rate securities may produce less income predicted interest rates fall basis points change spread companys interest rate sensitive investments would either increase decrease unrealized value cash equivalents current marketable securities approximately billion company access substantial sources funds numerous banks worldwide september company secured new day credit facility total credit available company approximates billion expires september interest charged borrowings credit line agreement based either secured overnight financing rate sofr reference rate applicable market rate allowed plus applicable margins commitment fees agreement material total borrowings end billion billion respectively decrease borrowings due repayment debt net debt cash current marketable securities net debt billion compared net debt billion total debt represented total capital shareholders equity total debt total capital shareholders equity per share end compared yearend summary borrowings found note consolidated financial statements dividends company increased dividend th consecutive year cash dividends paid per share per share january board directors declared regular cash dividend per share payable march shareholders record february information critical accounting policies estimates managements discussion analysis results operations financial condition based companys consolidated financial statements prepared accordance accounting principles generally accepted us gaap preparation financial statements requires management make estimates assumptions affect amounts reported revenues expenses assets liabilities related disclosures actual results may may differ estimates company believes understanding certain key accounting policies estimates essential achieving insight companys operating results financial condition key accounting policies include revenue recognition income taxes legal selfinsurance contingencies valuation longlived assets assumptions used determine amounts recorded pensions employee benefit plans accounting stock based awards extent covid impacts companys business financial results depend numerous evolving factors including limited magnitude duration covid extent impact worldwide macroeconomic conditions including interest rates employment rates health insurance coverage speed anticipated recovery governmental business reactions pandemic company assessed certain accounting matters generally require consideration forecasted financial information context information reasonably available company unknown future impacts covid january date report accounting matters assessed included limited companys allowance doubtful accounts credit losses inventory related reserves accrued rebates associated reserves carrying value goodwill longlived assets material impact companys consolidated financial statements year ended january companys future assessment magnitude duration covid well factors could result material impacts companys consolidated financial statements future reporting periods revenue recognition company recognizes revenue product sales obligations terms contract customer satisfied generally occurs transfer control goods customers company 's global payment terms typically days provisions certain rebates sales incentives trade promotions coupons product returns discounts customers governmental clawback provisions accounted variable consideration recorded reduction sales product discounts granted based terms arrangements direct indirect market participants well market conditions including consideration competitor pricing rebates estimated based contractual terms historical experience patient outcomes trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler thirdparty sellthrough market research data well internally generated information sales returns estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall sales returns reserve based historical return trends product market percent gross sales accordance companys accounting policies company generally issues credit customers returned goods companys sales returns reserves accounted accordance us gaap guidance revenue recognition right return exists sales returns reserves recorded full sales value sales returns consumer health pharmaceutical segments almost exclusively resalable sales returns certain franchises medical devices segment typically resalable material company infrequently exchanges products inventory returned products sales returns reserve total company approximately annual net trade sales fiscal years promotional programs product listing allowances cooperative advertising arrangements recorded period related sales continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs based estimated sales volumes incentive period recorded products soldthese arrangements evaluated determine appropriate amounts deferred recorded reduction revenue company also earns profitshare payments collaborative arrangements certain products included sales customers years presented profitshare payments less total revenues included sales customers addition company enters collaboration arrangements contain multiple revenue generating activities amounts due collaborative partners arrangements recognized activity performed delivered based relative selling price upfront fees received part arrangements deferred recognized performance period see note consolidated financial statements additional disclosures collaborations reasonably likely changes assumptions used calculate accruals rebates returns promotions anticipated material effect financial statements company currently discloses impact changes assumptions quarterly annual filing material financial statement impact tables show progression accrued rebates returns promotions reserve doubtful accounts reserve cash discounts segment business fiscal years ended january january consumer health segment balance beginning balance dollars millions period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million january million january recorded contra asset pharmaceutical segment balance beginning paymentscredits balance dollars millions period accruals end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million january million january recorded contra asset includes prior period adjustments medical devices segment balance beginning balance dollars millions period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million january million january recorded contra asset income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based enacted tax regulations rates future changes tax laws rates may affect recorded deferred tax assets liabilities company unrecognized tax benefits uncertain tax positions company follows us gaap prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return management believes changes estimates would material effect company 's results operations cash flows financial position company recorded deferred tax liabilities undistributed earnings prior december international subsidiaries company provided deferred taxes undistributed earnings subsequent january certain international subsidiaries earnings considered indefinitely reinvested company intends continue reinvest earnings international operations company decides later date repatriate earnings us company would required provide net tax effects amounts company estimates tax effect repatriation would approximately billion currently enacted tax laws regulations current currency exchange rates amount include possible benefit us foreign tax credits may substantially offset cost see note note consolidated financial statements information regarding income taxes legal self insurance contingencies company records accruals various contingencies including legal proceedings product liability claims arise normal course business accruals based managements judgment probability losses applicable actuarially determined estimates company self insurance whollyowned captive insurance company addition accruals self insurance program claims exceed insurance coverage accrued losses probable amounts reasonably estimated company follows provisions us gaap recording litigation related contingencies liability recorded loss probable reasonably estimated see notes consolidated financial statements information regarding product liability legal proceedings longlived intangible assets company assesses changes qualitatively quantitatively economic conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets assumptions estimates may change time may may necessary company record impairment charges employee benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide plans based assumptions discount rate expected return plan assets mortality rates expected salary increases healthcare cost trend rates attrition rates see note consolidated financial statements details rates stock based compensation company recognizes compensation expense associated issuance equity instruments employees services based type equity instrument fair value estimated date grant using either blackscholes option valuation model combination blackscholes option valuation model monte carlo valuation model expensed financial statements service period input assumptions used determining fair value expected life expected volatility riskfree rate expected dividend yield prior fiscal performance share units fair market value calculated three component goals date grant operational sales adjusted operational earnings per share relative total shareholder return beginning fiscal performance share units fair market value calculated two component goals date grant adjusted operational earnings per share relative total shareholder return fair values earnings per share goal performance share unit estimated date grant using fair market value shares time award discounted dividends paid performance share units vesting period fair value relative total shareholder return goal performance share unit estimated date grant using monte carlo valuation model see note consolidated financial statements additional information new accounting pronouncements refer note consolidated financial statements recently adopted accounting pronouncements recently issued accounting pronouncements yet adopted january economic market factors covid considerations business continuity company considered various internal external factors assessing potential impact covid business financial results based upon information available time follows operating model company diversified business model across healthcare industry flexibility designed manufacturing research development clinical operations commercial capabilities supply chain company continues leverage global manufacturing footprint dualsource capabilities closely monitoring maintaining critical inventory major distribution centers away highrisk areas help ensure adequate effective distribution business continuity robust active business continuity plans across company 's network instrumental preparing company events like covid ability meet majority patient consumer needs remains uninterrupted workforce company put procedures place protect essential workforce manufacturing distribution commercial research operations ensuring appropriate remote working protocols established employees liquidity company 's highquality credit rating allows company superior access financial capital markets foreseeable future domestic foreign legislation company continue assess evaluate ongoing global legislative efforts combat covid impact economies sectors participates currently recent legislative acts put place expected material impact companys operations fiscal company entered series contract manufacturing arrangements vaccine production third party contract manufacturing organizations arrangements provide company future supplemental commercial capacity vaccine production potentially transferable rights production capacity required amounts paid services delivered contractually obligated paid contract manufacturing organizations approximately billion reflected prepaid expenses assets accrued liabilities liabilities accounts company 's consolidated balance sheet upon execution agreement additionally company entered certain vaccine development cost sharing arrangements government related organizations company continues evaluate monitor internal external supply arrangements including contract emergent biosolutions related production activities bayview maryland facility company established global vaccine supply network addition internal manufacturing site leiden netherlands ten manufacturing sites involved production vaccine across different countries continents company believe disruption vaccine manufacturing site resulting delay would material financial impact companys consolidated financial statements results company aware products used environment decade policymakers consumers businesses expressed concerns rising cost healthcare response concerns company longstanding policy pricing products responsibly period us weighted average compound annual growth rate companys net price increases healthcare products prescription overthe counter drugs hospital professional products us consumer price index cpi company operates certain countries economic conditions continue present significant challenges company continues monitor situations take appropriate actions inflation rates continue effect worldwide economies consequently way companies operate company accounted operations argentina venezuela highly inflationary prior threeyear cumulative inflation rate surpassed material impact company 's results period face increasing costs company strives maintain profit margins cost reduction programs productivity improvements periodic price increases company exposed fluctuations currency exchange rates change value us dollar compared foreign currencies company sales income expense would increased decreased translation foreign sales approximately billion net income approximately billion governments around world consider various proposals make changes tax laws may include increasing decreasing existing statutory tax rates connection various government initiatives companies required disclose information tax authorities operations around world may lead greater audit scrutiny profits earned countries change statutory tax rate country would result revaluation companys deferred tax assets liabilities related particular jurisdiction period new tax law enacted change would result expense benefit recorded companys consolidated statement earnings company closely monitors proposals arise countries operates changes statutory tax rate may occur time related expense benefit recorded may material fiscal quarter year law change enacted company faces various worldwide healthcare changes may continue result pricing pressures includehealthcare cost containment government legislation relating sales promotions reimbursement healthcare products changes behavior spending patterns purchasers healthcare products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing healthcare insurance coverage result current global economic downturn may continue impact companys businesses company also operates environment increasingly hostile intellectual property rights firms filed abbreviated new drug applications biosimilar biological product applications us fda otherwise challenged coverage andor validity company 's patents seeking market generic biosimilar forms many companys key pharmaceutical products prior expiration applicable patents covering products event company successful defending patent claims challenged resulting lawsuits generic biosimilar versions products issue introduced market resulting potential substantial market share revenue losses products may result noncash impairment charge associated intangible asset also risk one competitors could launch generic biosimilar version product issue following regulatory approval even though one valid patents place legal proceedings johnson johnson certain subsidiaries involved various lawsuits claims regarding product liability intellectual property commercial employment indemnification matters governmental investigations legal proceedings arise time time ordinary course business company records accruals loss contingencies associated legal matters probable liability incurred amount loss reasonably estimated january company determined liabilities associated certain litigation matters probable reasonably estimated company accrued matters continue monitor related legal issue adjust accruals might warranted based new information developments accordance asc litigation regulatory matters discussed loss probable reasonably possible company unable estimate possible loss range loss beyond amounts accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions including timing related payments ability make estimates judgments affected various factors including among things whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute procedural jurisdictional issues uncertainty unpredictability number potential claims ability achieve comprehensive multiparty settlements complexity related crossclaims counterclaims andor numerous parties involved extent adverse awards judgments verdicts rendered company company record accrual loss determined probable reasonably estimated company 's opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued company 's balance sheet expected material adverse effect company 's financial position however resolution increase accruals one matters reporting period may material adverse effect company 's results operations cash flows period see note consolidated financial statements included item report information regarding legal proceedings common stock companys common stock listed new york stock exchange symbol jnj february record holders common stock company item quantitative qualitative disclosures market risk information called item incorporated herein reference item managements discussion analysis results operations financial condition liquidity capital resources financing market risk report note summary significant accounting policies financial instruments notes consolidated financial statements included item report item financial statements supplementary data index audited consolidated financial statements consolidated balance sheets consolidated statements earnings consolidated statements comprehensive income consolidated statements equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm pcaob id managements report internal control financial reporting johnson johnson subsidiaries consolidated balance sheets january january dollars millions except share per share amounts note assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes prepaid expenses receivables total current assets property plant equipment net notes intangible assets net notes goodwill notes deferred taxes income note assets total assets liabilities shareholders equity current liabilities loans notes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued compensation employee related obligations accrued taxes income note total current liabilities longterm debt note deferred taxes income note employee related obligations notes longterm taxes payable note liabilities total liabilities commitments contingencies note shareholders equity preferred stock without par value authorized unissued shares common stock par value per share note authorized shares issued shares accumulated comprehensive income loss note retained earnings less common stock held treasury cost note shares shares total shareholders equity total liabilities shareholders equity see notes consolidated financial statements johnson johnson subsidiaries consolidated statements earnings dollars shares millions except per share amounts note sales customers cost products sold gross profit selling marketing administrative expenses research development expense inprocess research development note interest income interest expense net portion capitalized note income expense net restructuring note earnings provision taxes income provision taxes income note net earnings net earnings per share notes basic diluted average shares outstanding notes basic diluted see notes consolidated financial statements johnson johnson subsidiaries consolidated statements comprehensive income dollars millions note net earnings comprehensive income loss net tax foreign currency translation securities unrealized holding gain loss arising period reclassifications earnings net change employee benefit plans prior service credit cost net amortization gain loss net amortization effect exchange rates net change derivatives hedges unrealized gain loss arising period reclassifications earnings net change comprehensive income loss comprehensive income tax effects comprehensive income fiscal years respectively foreign currency translation million million million securities million employee benefit plans million million million derivatives hedges million million million see notes consolidated financial statements johnson johnson subsidiaries consolidated statements equity dollars millions note accumulated common stock treasury retained comprehensive issued stock total earnings income loss amount amount balance december net earnings cash dividends paid per share employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance december net earnings cash dividends paid per share employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance january net earnings cash dividends paid per share employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance january see notes consolidated financial statements johnson johnson subsidiaries consolidated statements cash flows dollars millions note cash flows operating activities net earnings adjustments reconcile net earnings cash flows operating activities depreciation amortization property intangibles stock based compensation asset writedowns contingent consideration reversal net gain sale assetsbusinesses deferred tax provision credit losses accounts receivable allowances changes assets liabilities net effects acquisitions divestitures increasedecrease accounts receivable increase inventories increase accounts payable accrued liabilities increase current noncurrent assets decreaseincrease current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assetsbusinesses net acquisitions net cash acquired note purchases investments sales investments credit support agreements activity net primarily licenses milestones net cash used investing activities cash flows financing activities dividends shareholders repurchase common stock proceeds shortterm debt repayment shortterm debt proceeds longterm debt net issuance costs repayment longterm debt proceeds exercise stock optionsemployee withholding tax stock awards net credit support agreements activity net net cash used financing activities effect exchange rate changes cash cash equivalents increasedecrease cash cash equivalents cash cash equivalents beginning year note cash cash equivalents end year note supplemental cash flow data cash paid year interest interest net amount capitalized income taxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds employee withholding tax stock awards conversion debt acquisitions fair value assets acquired fair value liabilities assumed noncontrolling interests net cash paid acquisitions note see notes consolidated financial statements notes consolidated financial statements summary significant accounting policies principles consolidation consolidated financial statements include accounts johnson johnson subsidiaries company intercompany accounts transactions eliminated columns rows within tables may add due rounding percentages calculated using actual nonrounded figures description company business segments company approximately employees worldwide engaged research development manufacture sale broad range products healthcare field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer health pharmaceutical medical devices consumer health segment includes broad range products used baby care oral care skin healthbeauty overthe counter pharmaceutical womens health wound care markets products marketed general public sold online ecommerce retail outlets distributors throughout world pharmaceutical segment focused six therapeutic areas including immunology infectious diseases neuroscience oncology pulmonary hypertension cardiovascular metabolic diseases products segment distributed directly retailers wholesalers distributors hospitals healthcare professionals prescription use medical devices segment includes broad range products used orthopaedic surgery interventional solutions cardiovascular neurovascular vision fields products distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals eye care professionals clinics november company announced intention separate companys consumer health business intention create new publicly traded company company targeting completion planned separation months initial announcement new accounting standards recently adopted accounting standards new material accounting standards adopted fiscal recently issued accounting standards adopted january company assesses adoption impacts recently issued accounting standards financial accounting standards board company 's financial statements well material updates previous assessments companys annual report fiscal year ended january new material accounting standards issued fiscal impacted company asu reference rate reform mid financial conduct authority fca announced longer require banks submit rates london interbank offered rate libor hence market participants work transition alternative reference rates reference rate reform rely libor available end reference rate reform term used refer efforts undertaken regulators market participants introduce new reference rates based larger liquid population observable transactions company evaluated implications reference rate reform applicable financial reporting guidance asu reference rate reform topic facilitation effects reference rate reform financial reporting key financial commercial contracts referenced libor including hedging relationships contracts reviewed mature prior termination libor modified apply new reference rate primarily secured overnight financing rate sofr applicable company also applied available practical expedients asc scope financial commercial contracts previously referenced libor applicable result company 's implementation reference rate reform provisions commercial financial contracts result material change company cash equivalentsthe company classifies highly liquid investments stated maturities three months less date purchase cash equivalents highly liquid investments stated maturities greater three months date purchase current marketable securities company policy making investments commercial institutions least investment grade credit rating company invests cash primarily government securities obligations corporate debt securities money market funds reverse repurchase agreements rras rras collateralized deposits form government securities obligations amount less value company record asset liability company permitted sell repledge associated collateral company policy collateral least equivalent credit rating company utilizes third party custodian manage exchange funds ensure collateral received maintained value rras daily basis rras stated maturities greater three months date purchase classified marketable securities investments investments classified held maturity investments reported amortized cost realized gains losses reported earnings investments classified availableforsale debt securities carried estimated fair value unrealized gains losses recorded component accumulated comprehensive income availableforsale securities available current operations classified current assets otherwise classified long term management determines appropriate classification investment debt equity securities time purchase reevaluates determination balance sheet date company reviews investments impairment adjusts investments fair value earnings required property plant equipment depreciation property plant equipment stated cost company utilizes straightline method depreciation estimated useful lives assets building building equipment years land leasehold improvements years machinery equipment years company capitalizes certain computer software development costs included machinery equipment incurred connection developing obtaining computer software internal use capitalized software costs amortized estimated useful lives software generally range years company reviews longlived assets assess recoverability using undiscounted cash flows certain events changes operating economic conditions occur impairment assessment may performed recoverability carrying value assets asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows revenue recognition company recognizes revenue product sales obligations terms contract customer satisfied generally occurs transfer control goods customers company 's global payment terms typically days provisions certain rebates sales incentives trade promotions coupons product returns discounts customers governmental clawback provisions accounted variable consideration recorded reduction sales liability recognized within accrued rebates returns promotions consolidated balance sheet product discounts granted based terms arrangements direct indirect market participants well market conditions including consideration competitor pricing rebates estimated based contractual terms historical experience patient outcomes trend analysis projected market conditions various markets served significant portion liability related rebates sale company 's pharmaceutical products within us primarily managed care medicare medicaid programs amounted billion billion january january respectively company evaluates market conditions products groups products primarily analysis wholesaler thirdparty sellthrough market research data well internally generated information sales returns estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall sales returns reserve based historical return trends product market percent gross sales accordance companys accounting policies company generally issues credit customersfor returned goods companys sales returns reserves accounted accordance us gaap guidance revenue recognition right return exists sales returns reserves recorded full sales value sales returns consumer health pharmaceutical segments almost exclusively resalable sales returns certain franchises medical devices segment typically resalable material company infrequently exchanges products inventory returned products sales returns reserve total company approximately annual net trade sales fiscal years promotional programs product listing allowances cooperative advertising arrangements recorded period related sales continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs based estimated sales volumes incentive period recorded products sold arrangements evaluated determine appropriate amounts deferred recorded reduction revenue company also earns profitshare payments collaborative arrangements certain products included sales customers years presented profitshare payments less total revenues included sales customers see note consolidated financial statements disaggregation revenue shipping handling shipping handling costs incurred billion billion billion fiscal years respectively included selling marketing administrative expense amount revenue received shipping handling less sales customers periods presented inventories inventories stated lower cost net realizable value determined firstin firstout method intangible assets goodwill authoritative literature us gaap requires goodwill intangible assets indefinite lives assessed annually impairment company completed annual impairment test fiscal fourth quarter future impairment tests performed annually fiscal fourth quarter sooner warranted purchased inprocess research development accounted indefinite lived intangible asset underlying project completed point intangible asset accounted definite lived intangible asset abandoned point intangible asset written partially impaired intangible assets finite useful lives continue amortized useful lives reviewed impairment warranted economic conditions see note details intangible assets goodwill financial instruments required us gaap derivative instruments recorded balance sheet fair value fair value exit price would received sell asset paid transfer liability fair value marketbased measurement determined using assumptions market participants would use pricing asset liability authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value level highest priority level lowest changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction company documents relationships hedged items derivatives overall risk management strategy includes reasons undertaking hedge transactions entering derivatives objectives strategy minimize foreign currency exposures impact companys financial performance protect companys cash flow adverse movements foreign exchange rates ensure appropriateness financial instruments manage enterprise risk associated financial institutions see note additional information financial instruments leases company determines whether arrangement lease contract inception establishing contract conveys right control use identified property plant equipment period time exchange consideration right use rou assets lease liabilities operating leases included assets accrued liabilities liabilities consolidated balance sheet rou assets represent right use underlying asset lease term lease liabilities represent obligation make lease payments arising lease commitments finance leases significant included property plant equipment loans notes payable longterm debt consolidated balance sheet rou assets lease liabilities recognized lease commencement date based present value minimum lease payments lease term company uses incremental borrowing rate based informationavailable commencement date determining present value lease payments implicit rate readily determinable lease terms may include options extend terminate lease options included lease term reasonably certain company exercise option operating lease expense recognized straightline basis lease term company elected following policy elections adoption use portfolio approach leases assets master service agreements exclusion short term leases balance sheet separating lease nonlease components company primarily operating lease space vehicles manufacturing equipment data processing equipment rou asset pertaining operating leases billion billion respectively lease liability billion billion respectively operating lease costs billion billion billion respectively cash paid amounts included measurement lease liabilities billion billion billion respectively product liability accruals product liability claims recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information actuarially determined estimates applicable accruals adjusted periodically additional information becomes available company accrues estimate legal defense costs needed defend matter costs probable reasonably estimated extent adverse verdicts rendered company company record accrual loss determined probable reasonably estimated company self insurance whollyowned captive insurance company addition accruals self insurance program claims exceed insurance coverage accrued losses probable amounts reasonably estimated research development research development expenses expensed incurred accordance asc research development upfront milestone payments made third parties connection research development collaborations expensed incurred point regulatory approval payments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized payments included intangibles net accumulated amortization company enters collaborative arrangements typically pharmaceutical biotechnology companies develop commercialize drug candidates intellectual property arrangements typically involve two parties active participants collaboration exposed significant risks rewards dependent commercial success activities collaborations usually involve various activities one parties including research development marketing selling distribution often collaborations require upfront milestone royalty profit share payments contingent upon occurrence certain future events linked success asset development amounts due collaborative partners related development activities generally reflected reduction research development expense performance contract development services central companys operations general income statement presentation collaborations follows naturetype collaboration statement earnings presentation thirdparty sale product profit share payments received sales customers royaltiesmilestones paid collaborative partner post cost products sold regulatory approval royalties received collaborative partner income expense net upfront payments milestones paid collaborative partner research development expense preregulatory approval research development payments collaborative partner research development expense research development payments received reduction research development expense collaborative partner government entity milestones capitalized intangible assets amortized cost products sold useful life years presented individual project represented greater total annual consolidated research development expense company number products compounds developed collaboration strategic partners including xarelto codeveloped bayer healthcare ag imbruvica developed collaboration comarketed pharmacyclics llc abbvie company separately company number licensing arrangements products compounds including darzalex licensed genmab advertising costs associated advertising expensed year incurred included selling marketing administrative expenses advertising expenses worldwide comprised television radio print media internet advertising billion billion billion fiscal years respectively income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based enacted tax regulations rates future changes tax laws rates may affect recorded deferred tax assets liabilities future company unrecognized tax benefits uncertain tax positions company follows us gaap prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return management believes changes estimates would material effect company 's results operations cash flows financial position united states enacted law new us tax legislation us tax cuts jobs act tcja law included provisions comprehensive overhaul corporate income tax code including reduction statutory corporate tax rate effective january tcja included provision tax previously undistributed earnings us companies located foreign jurisdictions undistributed earnings form cash cash equivalents taxed rate earnings taxed rate tax payable years accrue interest payments began continue remaining balance end approximately billion billion classified noncurrent reflected longterm taxes payable companys balance sheet balance account related receivables tax authorities expected received next months tcja also includes provisions tax global intangible lowtaxed income gilti gilti described excess us shareholders total net foreign income deemed return tangible assets provided tcja january fasb issued guidance allows companies elect accounting policy whether record tax effects gilti period tax liability generated ie period cost provide deferred tax assets liabilities related basis differences exist expected effect amount gilti inclusion future years upon reversal ie deferred method company elected account gilti deferred method deferred tax amounts recorded based evaluation temporary differences expected reverse gilti incurred future periods company recorded deferred tax liabilities undistributed earnings prior december international subsidiaries company provided deferred taxes undistributed earnings subsequent january certain international subsidiaries earnings considered indefinitely reinvested company intends continue reinvest earnings international operations company decides later date repatriate earnings us company would required provide net tax effects amounts company estimates tax effect repatriation would approximately billion currently enacted tax laws regulations current currency exchange rates amount include possible benefit us foreign tax credits may substantially offset cost see note consolidated financial statements information regarding income taxes net earnings per share basic earnings per share computed dividing net earnings available common shareholders weighted average number common shares outstanding period diluted earnings per share reflects potential dilution could occur securities exercised converted common stock using treasury stock method use estimates preparation consolidated financial statements conformity accounting principles generally accepted us requires management make estimates assumptions affect amounts reported estimates used accounting sales discounts rebates allowances incentives product liabilities income taxes withholding taxes depreciation amortization employee benefits contingencies intangible asset liability valuations actual results may may differ estimates company follows provisions us gaap recording litigation related contingencies liability recorded loss probable reasonably estimated best estimate loss within range accrued however estimate range better minimum amount accrued extent covid impacts companys business financial results depend numerous evolving factors including limited magnitude duration covid extent impact worldwide macroeconomic conditions including interest rates employment rates health insurance coverage speed anticipated recovery governmental business reactions pandemic company assessed certain accounting matters generally require consideration forecasted financial information context information reasonably available company unknown future impacts covid january date report accounting matters assessed included limited companys allowance doubtful accounts credit losses inventory related reserves accrued rebates associated reserves carrying value goodwill otherlonglived assets along companys ongoing vaccine development distribution efforts material impact companys consolidated financial statements fiscal year ended january companys future assessment magnitude duration covid well factors could result material impacts companys consolidated financial statements future reporting periods annual closing date company follows concept fiscal year ends sunday nearest end month december normally fiscal year consists weeks every five six years fiscal year consists weeks therefore includes additional shipping days case fiscal year case fiscal year reclassification certain prior period amounts reclassified conform current year presentation cash cash equivalents current marketable securities end fiscal year cash cash equivalents current marketable securities comprised dollars millions current carrying unrecognized estimated cash cash marketable amount loss fair value equivalents securities cash nonus sovereign securities us reverse repurchase agreements corporate debt securities money market funds time deposits subtotal us gov't securities sovereign securities corporate debt securities subtotal available sale total cash cash equivalents current marketable securities dollars millions current carrying unrecognized estimated cash cash marketable amount gain fair value equivalents securities cash nonus sovereign securities us reverse repurchase agreements corporate debt securities money market funds time deposits subtotal gov't securities sovereign securities corporate debt securities subtotal available sale total cash cash equivalents current marketable securities held maturity investments reported amortized cost realized gains losses reported earnings available sale debt securities reported fair value unrealized gains losses reported net taxes comprehensive income fair value government securities obligations corporate debt securities estimated using quoted broker prices significant observable inputs contractual maturities available sale debt securities january follows cost basis fair value dollars millions due within one year due one year five years due five years ten years total debt securities company invests excess cash deposits major banks throughout world highquality money market instruments company policy making investments commercial institutions least investment grade credit rating inventories end fiscal years inventories comprised dollars millions raw materials supplies goods process finished goods total inventories property plant equipment end fiscal years property plant equipment cost accumulated depreciation dollars millions land land improvements buildings building equipment machinery equipment construction progress total property plant equipment gross less accumulated depreciation total property plant equipment net company capitalizes interest expense part cost construction facilities equipment interest expense capitalized fiscal years million million million respectively depreciation expense including amortization capitalized interest fiscal years billion billion billion respectively upon retirement disposal property plant equipment costs related amounts accumulated depreciation amortization eliminated asset accumulated depreciation accounts respectively difference net asset value proceeds recorded earnings intangible assets goodwill end fiscal years gross net amounts intangible assets dollars millions intangible assets definite lives patents trademarks gross less accumulated amortization patents trademarks net customer relationships intangibles gross less accumulated amortization customer relationships intangibles net intangible assets indefinite lives trademarks purchased inprocess research development total intangible assets indefinite lives total intangible assets net majority comprised customer relationships fiscal company recorded partial iprd impairment charge billion primarily related expected development delays general surgery digital robotics platform ottava acquired auris health acquisition impairment charge calculated based revisions discounted cash flow valuation model reflecting delay first human procedures approximately two years initial acquisition model assumption second half remaining reduction driven assets reached commercialization classified definite lives goodwill january january allocated segment business follows dollars millions consumer health pharmaceutical medical devices total goodwill december goodwill related acquisitions currency translationother goodwill january goodwill related acquisitions goodwill related divestitures currency translationother goodwill january weighted average amortization period patents trademarks years weighted average amortization period customer relationships intangible assets years amortization expense amortizable assets included cost products sold billion billion billion tax fiscal years ended january january december respectively intangible asset writedowns included income expense net estimated amortization expense approved products tax five succeeding years approximately dollars millions see note consolidated financial statements additional details related acquisitions divestitures fair value measurements company uses forward foreign exchange contracts manage exposure variability cash flows primarily related foreign exchange rate changes future intercompany products thirdparty purchases materials denominated foreign currency company uses cross currency interest rate swaps manage currency risk primarily related borrowings types derivatives designated cash flow hedges additionally company uses interest rate swaps instrument manage interest rate risk related fixed rate borrowings derivatives designated fair value hedges company uses cross currency interest rate swaps forward foreign exchange contracts designated net investment hedges additionally company uses forward foreign exchange contracts offset exposure certain foreign currency assets liabilities forward foreign exchange contracts designated hedges therefore changes fair values derivatives recognized earnings thereby offsetting current earnings effect related foreign currency assets liabilities company enter derivative financial instruments trading speculative purposes contain credit risk related contingent features company maintains credit support agreements csa certain derivative counterparties establishing collateral thresholds based respective credit ratings netting agreements january total amount cash collateral paid company csa amounted million net related net investment cash flow hedges ongoing basis company monitors counterparty credit ratings company considers credit nonperformance risk low company primarily enters agreements commercial institutions least investment grade credit rating refer table significant financial assets liabilities measured fair value contained footnote receivables payables commercial institutions january company notional amounts outstanding forward foreign exchange contracts cross currency interest rate swaps interest rate swaps billion billion billion respectively january company notional amounts outstanding forward foreign exchange contracts cross currency interest rate swaps billion billion respectively derivative instruments recorded balance sheet fair value changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction designation cash flow hedge made entrance date derivative contract inception derivatives expected highly effective foreign exchange contracts designated cash flow hedges accounted forward method gainslosses associated contracts recognized income statement hedged item impacts earnings changes fair value derivatives recorded accumulated comprehensive income underlying transaction affects earnings reclassified earnings account hedged transaction gains losses associated interest rate swaps changes fair value hedged debt attributable changes interest rates recorded interest expense period occur gains losses net investment hedge accounted currency translation account within accumulated comprehensive income portion excluded effectiveness testing recorded interest income expense using spot method ongoing basis company assesses whether derivative continues highly effective offsetting changes hedged items derivative longer expected highly effective hedge accounting discontinued company designated euro denominated notes issued may due dates ranging net investment hedge company 's investments certain international subsidiaries use euro functional currency order reduce volatility caused changes exchange rates january balance deferred net loss derivatives included accumulated comprehensive income million aftertax additional information see consolidated statements comprehensive income note company expects substantially amounts related forward foreign exchange contracts reclassified earnings next months result transactions expected occur period maximum length time company hedging transaction exposure months excluding interest rate contracts net investment hedges amount ultimately realized earnings may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity derivative following table summary activity related derivatives hedges fiscal years ended january january net tax january january cost interest cost interest products rd income income products rd income income sales sold expense expense expense sales sold expense expense expense dollars millions effects fair value net investment cash flow hedging gain loss fair value hedging relationship interest rate swaps contracts hedged items derivatives designated hedging instruments gain loss net investment hedging relationship cross currency interest rate swaps contracts amount gain loss recognized income derivative amount excluded effectiveness testing amount gain loss recognized aoci gain loss cash flow hedging relationship forward foreign exchange contracts amount gain loss reclassified aoci income amount gain loss recognized aoci cross currency interest rate swaps contracts amount gain loss reclassified aoci income amount gain loss recognized aoci january january following amounts recorded consolidated balance sheet related cumulative basis adjustment fair value hedges line item consolidated balance cumulative amount fair value hedging sheet hedged item adjustment included carrying included carrying amount hedged liability amount hedged liability january january january january dollars millions longterm debt following table effect derivatives designated hedging instrument fiscal years ended january january location gain loss gainloss recognized income recognized dollars millions derivative income derivative derivatives designated hedging instruments january january income expense foreign exchange contracts following table effect net investment hedges fiscal years ended january january gainloss location gain loss reclassified gainloss reclassified recognized accumulated accumulated oci accumulated oci comprehensive income income income january january january dollars millions january debt interest income expense cross currency interest rate swaps interest income expense company holds equity investments readily determinable fair values equity investments without readily determinable fair values company measures equity investments readily determinable fair values cost minus impairment plus minus changes resulting observable price changes orderly transactions identical similar investment issuer following table summary activity related equity investments fiscal years ended january january january january changes fair sales value reflected non current purchasesother dollars millions carrying value net income carrying value assets equity investments readily determinable value equity investments without readily determinable value december january changes fair sales value reflected non current purchasesother dollars millions carrying value net income carrying value assets equity investments readily determinable value equity investments without readily determinable value recorded incomeexpense includes impact currency fiscal years ended january january equity investments without readily determinable market values million million respectively changes fair value reflected net income result impairments offsetting impacts million million respectively changes fair value reflected net income due changes observable prices gains disposal investments impact fiscal driven gain disposal grail investment fair value exit price would received sell asset paid transfer liability fair value marketbased measurement determined using assumptions market participants would use pricing asset liability accordance asc threelevel hierarchy prioritize inputs used measuring fair value levels within hierarchy described level highest priority level lowest fair value derivative financial instrument ie forward foreign exchange contracts interest rate contracts aggregation currency future cash flows discounted present value prevailing market interest rates subsequently converted us dollar current spot foreign exchange rate company believe fair values derivative instruments materially differ amounts could realized upon settlement maturity changes fair value material effect companys results operations cash flows financial position company also holds equity investments classified level debt securities classified level company holds acquisition related contingent liabilities based upon certain regulatory commercial events classified level whose values determined using discounted cash flow methodologies similar techniques determination fair value requires significant judgment estimations following three levels inputs used measure fair value level quoted prices active markets identical assets liabilities level significant observable inputs level significant unobservable inputs companys significant financial assets liabilities measured fair value fiscal year ended january january follows dollars millions level level level total total derivatives designated hedging instruments assets forward foreign exchange contracts interest rate contracts total liabilities forward foreign exchange contracts interest rate contracts total derivatives designated hedging instruments assets forward foreign exchange contracts liabilities forward foreign exchange contracts available sale investments equity investments debt securities liabilities contingent consideration gross net derivative reconciliation dollars millions total gross assets credit support agreement csa total net asset total gross liabilities credit support agreement csa total net liabilities summarized information changes liabilities contingent consideration follows dollars millions beginning balance changes estimated fair value additions payments ending balance assets liabilities classified level exception equity investments million classified level contingent consideration million classified level includes cross currency interest rate swaps interest rate swaps classified noncurrent assets classified cash equivalents current marketable securities includes million million million classified noncurrent liabilities january january december respectively includes million million million classified current liabilities january january december respectively ongoing fair value adjustment amounts recorded primarily research development expense company recorded contingent consideration reversal million related timing certain developmental milestones associated auris health acquisition reversal contingent consideration recorded income expense see notes financial assets liabilities held carrying amount consolidated balance sheet borrowings components longterm debt follows effective effective rate rate dollars millions notes due notes due notes due notes due b euro b euro notes due debentures due notes due notes due notes due mm euro mm euro notes due mm gbp mm gbp notes due notes due notes due notes due notes due notes due mm euro mm euro notes due notes due notes due debentures due notes due notes due b euro b euro notes due notes due notes due debentures due notes due debentures due notes due notes due notes due notes due notes due notes due notes due notes due subtotal less current portion total longterm debt weighted average effective rate translation rate january translation rate january excess fair value carrying value debt billion end fiscal year billion end fiscal year fair value longterm debt estimated using market prices corroborated quoted broker prices significant observable inputs company access substantial sources funds numerous banks worldwide september company secured new day credit facility total credit available company approximates billion expires september interest charged borrowings credit line agreement based either term sofr reference rate applicable market rates allowed terms agreement plus applicable margins commitment fees agreements material throughout fiscal years company continued access liquidity commercial paper market shortterm borrowings current portion longterm debt amounted approximately billion billion end fiscal years respectively current portion long term debt billion billion respectively remainder commercial paper local borrowing international subsidiaries current debt balance january includes billion commercial paper weighted average interest rate weighted average maturity approximately three months aggregate maturities longterm debt obligations commencing dollars millions income taxes provision taxes income consists dollars millions currently payable us taxes international taxes total currently payable deferred us taxes international taxes total deferred provision taxes income comparison income tax expense us statutory rate fiscal years companys effective tax rate follows dollars millions us international earnings taxes income tax rates us statutory rate international operations us taxes international income tax benefits loss capital assets tax benefits sharebased compensation tcja related impacts effective rate periods presented company subsidiaries operating puerto rico various tax incentives international operations reflects impacts operations jurisdictions statutory tax rates different us particularly ireland switzerland puerto rico favorable impact effective tax rate compared us statutory rate amounts include reorganization international subsidiaries amounts include impact new tax legislation enactment switzerland described includes impact gilti tax foreignderived intangible income deduction foreign income taxable us tax code amounts include reorganization international subsidiaries amounts include impact new tax legislation enactment switzerland described represents impact adjustments balances originally recorded part tcja provisional tax charge information provided fiscal year tax rate decreased compared fiscal year tax rate primarily driven following items fiscal year company reorganized ownership structure certain whollyowned international subsidiaries part reorganization company increased tax basis certain assets fair value accordance applicable local regulations net impact restructuring approximately billion net benefit benefit companys annual effective tax rate comprised following items approximately billion local deferred tax assets record remeasurement tax basis assets fair value benefit reflected international operations companys effective tax rate reconciliation approximately billion us deferred tax expense relating gilti deferred tax liability resulting remeasurement deferred tax assets expense reflected us tax international income companys effective tax rate reconciliation also fiscal fourth quarter company recognized loss certain us affiliates related previously impaired book value certain intangibles reduced tax rate approximately reflected tax benefits loss capital assets effective tax rate reconciliation additionally fiscal impacts rate primarily driven litigation acquisition related items follows company accrued additional legal expenses approximately billion talc effective tax rate billion risperdal settlements effective tax rate see note consolidated financial statements details company recorded partial iprd charge billion ottava intangible asset acquired auris health acquisition effective rate see notes consolidated financial statements details fiscal year tax rate decreased compared fiscal year tax rate primarily driven following items fiscal year switzerland enacted federal act tax reform ahv financing traf became effective january federal transitional provisions traf allow companies certain conditions adjust tax basis certain assets fair value ie stepup depreciated amortized resulting incremental swiss tax deduction transitional periodtraf also provides parameters enable swiss cantons establish localized tax rates regulations companies new cantonal tax parameters include favorable tax benefits patents additional research development tax deductions cantonal transitional provisions traf allowed companies elect either tax basis stepup similar federal transition benefit alternative statutory tax rate period exceed years company currently operations located various swiss cantons fiscal year described detail company recorded impacts traf enacted period fiscal year final canton company maintains significant operations enacted traf legislation additionally company received rulings swiss federal cantonal tax authorities remaining jurisdictions significant operations rulings resulted company revising estimate tax basis adjustment ie stepup assets result company recorded additional deferred tax benefits company recognized net benefit fiscal year swiss tax reform approximately billion benefit companys annual effective tax rate comprised following items approximately billion tax benefit relating remeasurement swiss deferred tax assets liabilities change federal cantonal tax rates enactment occurred fiscal year benefit reflected international operations companys effective tax rate reconciliation million deferred tax asset related estimated value federal tax basis stepup companys swiss subsidiaries assets described benefit reflected international operations companys effective tax rate reconciliation approximately billion us deferred tax expense relating gilti deferred tax liability resulting remeasurement swiss deferred tax assets liabilities fiscal year benefit reflected us tax international income companys effective tax rate reconciliation company expect receive future rulings regarding transitional provisions traf also fiscal year company recognized capital loss certain us affiliates related previously impaired book value certain intangibles reduced tax rate approximately reflected tax benefits loss capital assets effective tax rate reconciliation addition fiscal year company lower income higher tax jurisdictions primarily driven impact accrual litigation costs related talc billion reduced us earnings taxes effective tax rate accrual additional legal costs including additional billion associated revised agreement principle settle opioid litigation effective tax rate company also reduced contingent consideration liability related auris health acquisition see note reversed unrecognized tax benefits due completion several years tax examinations certain jurisdictions fiscal year fiscal year company reorganized ownership structure certain whollyowned international subsidiaries fiscal fourth quarter resulted reduction certain withholding local taxes previously recognized part provisional tax cuts jobs act tcja tax charge fiscal year finalized fiscal year following completion restructuring approval applicable local authorities company reversed deferred tax liability billion related deferred tax asset billion us foreign tax credits net deferred tax benefit billion decreasing annual effective tax rate benefit reflected tcja related impacts companys effective tax rate reconciliation following items also impacted fiscal year effective tax rate impact agreement principle settle opioid litigation billion see note consolidated financial statements reduced us earnings taxes effective tax rate decreased companys annual effective tax rate approximately december fiscal year us treasury issued final foreign tax credit regulations resulted company revising amount foreign tax credits initially recorded fiscal year part provisional tcja tax charge result company recorded increased deferred tax asset related foreign tax credits approximately billion annual effective tax rate benefit reflected tcja related impacts companys effective tax rate reconciliation company reassessed uncertain tax positions related current irs audit increased unrecognized tax benefit billion liability increased annual effective tax rate approximately see sectionon unrecognized tax benefits additional information positions related uncertain tax regarding international transfer pricing expense classified international operations companys effective tax rate reconciliation described swiss tax legislation fiscal year company recorded net tax expense billion increased effective tax rate fiscal year approximately net tax expense related federal certain cantonal enactments fiscal year consisting following provisions approximately billion tax expense relating remeasurement swiss deferred tax assets liabilities change federal cantonal tax rates enactment occurred december expense reflected international operations companys effective tax rate reconciliation billion deferred tax asset related estimated value federal tax basis stepup companys swiss subsidiaries assets benefit reflected international operations companys effective tax rate reconciliation approximately million us deferred tax expense relating gilti deferred tax liability resulting remeasurement swiss deferred tax assets liabilities new deferred tax asset federal stepup benefit reflected us tax international income companys effective tax rate reconciliation temporary differences carryforwards end fiscal years follows deferred tax deferred tax dollars millions asset liability asset liability employee related obligations stock based compensation depreciation property plant equipment goodwill intangibles rd capitalized tax reserves liabilities income reported tax purposes net realizable operating loss carryforward undistributed foreign earnings global intangible lowtaxed income miscellaneous international miscellaneous us total deferred income taxes certain prior year amounts reclassified conform current year presentation amount inclusive billion deferred tax asset established part reorganized ownership structure certain whollyowned international subsidiaries previously described company whollyowned international subsidiaries cumulative net losses company believes likely subsidiaries generate future taxable income sufficient utilize deferred tax assets however certain jurisdictions valuation allowances recorded deferred tax assets loss carryforwards likely realized valuation allowances material following table summarizes activity related unrecognized tax benefits dollars millions beginning year increases related current year tax positions increases related prior period tax positions decreases related prior period tax positions settlements lapse statute limitations end year unrecognized tax benefits billion january recognized would affect companys annual effective tax rate company conducts business files tax returns numerous countries currently tax audits progress number tax authorities respect united states irs completed audit tax years currently auditing tax years fiscal year company made final payments approximately billion us treasury related final settlement tax audit liability major jurisdictions company conducts business years remain open tax audit go back year company believes possible tax audits may completed next twelve months taxing authorities jurisdictions outside united states however company able provide reasonably reliable estimate timing future tax payments relating uncertain tax positions company classifies liabilities unrecognized tax benefits related interest penalties longterm liabilities except previously noted amounts related current united states irs audit interest expense penalties related unrecognized tax benefits classified income tax expense company recognized tax interest expense million million million fiscal years respectively total amount accrued interest million million fiscal years respectively employee related obligations end fiscal fiscal employee related obligations recorded consolidated balance sheets dollars millions pension benefits postretirement benefits postemployment benefits deferred compensation total employee obligations less current benefits payable employee related obligations noncurrent prepaid employee related obligations million million respectively included assets consolidated balance sheets pensions benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide company also provides postretirement benefits primarily healthcare eligible us retired employees dependents many international employees covered governmentsponsored programs cost company significant us nonunion pension benefits employees hired january primarily based employees compensation last five years retirement number years service final average pay formula us pension benefits employees hired calculated using different formula based employee compensation total years service retirement value formula january company announced effective january eligible us nonunion employees regardless hire date earn benefits retirement value formula amendment affect benefits accrued final average pay formula service january impact change decreases projected benefit obligation january approximately billion included amendments line change benefit obligation international subsidiaries plans funds deposited trustees annuities purchased group contracts reserves provided company fund retiree healthcare benefits advance right modify plans future company used december december respectively measurement date us international retirement benefit plans net periodic benefit costs companys defined benefit retirement plans benefit plans include following components retirement plans benefit plans dollars millions service cost interest cost expected return plan assets amortization prior service cost recognized actuarial losses gains curtailments settlements net periodic benefit cost service cost component net periodic benefit cost presented line items consolidated statement earnings employee compensation costs reported including cost products sold research development expense selling marketing administrative expenses components net periodic benefit cost presented part income expense net consolidated statement earnings unrecognized gains losses us pension plans amortized average remaining future service plan plans active employees amortized average life expectancy amortization gains losses us benefit plans determined using corridor greater market value assets accumulated postretirement benefit obligation total unamortized gains losses excess corridor amortized average remaining future serviceprior service costsbenefits us pension plans amortized average remaining future service plan participants time plan amendment prior service costbenefit us benefit plans amortized average remaining service full eligibility age plan participants time plan amendment following table represents weightedaverage actuarial assumptions retirement plans benefit plans worldwide benefit plans net periodic benefit cost service cost discount rate interest cost discount rate rate increase compensation levels expected longterm rate return plan assets benefit obligation discount rate rate increase compensation levels companys discount rates determined considering current yield curves representing high quality longterm fixed income instruments resulting discount rates consistent duration plan liabilities company 's methodology determining service interest cost uses duration specific spot rates along yield curve plans ' liability cash flows expected rates return plan asset assumptions represent company 's assessment longterm returns diversified investment portfolios globally assessment determined using projections external financial sources longterm historical averages actual returns asset class various asset class allocations market following table displays assumed healthcare cost trend rates individuals healthcare plans healthcare cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend year rate reaches ultimate trend rate following table sets forth information related benefit obligation fair value plan assets fiscal yearend companys defined benefit retirement plans postretirement plans retirement plans benefit plans dollars millions change benefit obligation projected benefit obligation beginning year service cost interest cost plan participant contributions amendments actuarial gains losses divestitures acquisitions curtailments settlements restructuring benefits paid plan effect exchange rates projected benefit obligation end year change plan assets plan assets fair value beginning year actual return plan assets company contributions plan participant contributions settlements divestitures acquisitions benefits paid plan assets effect exchange rates plan assets fair value end year funded status end year amounts recognized companys balance sheet consist following noncurrent assets current liabilities noncurrent liabilities total recognized consolidated balance sheet end year amounts recognized accumulated comprehensive income consist following net actuarial loss prior service cost credit unrecognized net transition obligation total tax effects accumulated benefit obligations end year january company announced effective january eligible us nonunion employees regardless hire date earn benefits retirement value formula amendment affect benefits accrued final average pay formula service january actuarial gain retirement plans primarily related increases discount rates actuarial losses retirement plans primarily related decreases discount rates retirement plans benefit plans dollars millions amounts recognized net periodic benefit cost comprehensive income net periodic benefit cost net actuarial gain loss amortization net actuarial loss prior service cost credit amortization prior service cost credit effect exchange rates total lossincome recognized comprehensive income tax total recognized net periodic benefit cost comprehensive income company plans continue fund us qualified plans comply pension protection act international plans funded accordance local regulations additional discretionary contributions made deemed appropriate meet longterm obligations plans certain plans funding common practice funding provides economic benefit consequently company several pension plans funded company contributed million million us international pension plans respectively following table displays funded status company 's us qualified nonqualified pension plans international funded unfunded pension plans december december respectively us plans international plans qualified plans nonqualified plans funded plans unfunded plans dollars millions plan assets projected benefit obligation accumulated benefit obligation funded status projected benefit obligation accumulated benefit obligation plans accumulated benefit obligations excess plan assets accumulated benefit obligation projected benefit obligation plan assets billion billion billion respectively end billion billion billion respectively end following table displays projected future benefit payments companys retirement benefit plans dollars millions projected future benefit payments retirement plans benefit plans following table displays projected future minimum contributions unfunded retirement plans amounts include discretionary contributions company may elect make future dollars millions projected future contributions pension plan overseen local committee board responsible overall administration investment pension plans determining investment policies strategies goals committee board considers factors including local pension rules regulations local tax regulations availability investment vehicles separate accounts commingled accounts insurance funds etc funded status plans ratio actives retirees duration liabilities relevant factors including diversification liquidity local markets liquidity base currency majority companys pension funds open new entrants expected ongoing plans permitted investments primarily liquid andor listed little reliance illiquid nontraditional investments hedge funds companys retirement plan asset allocation end target allocations follows percent target plan assets allocation worldwide retirement plans equity securities debt securities total plan assets determination fair value plan assets plan established welldocumented process determining fair values fair value based upon quoted market prices available listed prices quotes available fair value based upon models primarily use inputs marketbased independently sourced market parameters including yield curves interest rates volatilities equity debt prices foreign exchange rates credit curves plan believes valuation methods appropriate consistent market participants use different methodologies assumptions determine fair value certain financial instruments could result different estimate fair value reporting date valuation hierarchy authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value levels within hierarchy described table level highest priority level lowest net asset value nav based value underlying assets owned fund minus liabilities divided number shares outstanding financial instruments categorization within valuation hierarchy based upon lowest level input significant fair value measurement following description valuation methodologies used investments measured fair value shortterm investment funds cash quoted shortterm instruments valued closing price amount held deposit custodian bank investments investment vehicles valued using nav provided administrator fund nav quoted price market active classified level government agency securities limited number investments valued closing price reported major market individual securities traded quoted prices available active market investments classified within level valuation hierarchy quoted market prices available specific security fair values estimated using pricing models quoted prices securities similar characteristics discounted cash flows quoted market prices security available active market classified level debt instruments limited number investments valued closing price reported major market individual securities traded quoted prices available active market investments classified level quoted market prices available specific security fair values estimated using pricing models quoted prices securities similar characteristics discounted cash flows classified level level debt instruments priced based unobservable inputs equity securities equity securities valued closing price reported major market individual securities traded substantially equity securities classified within level valuation hierarchy commingled funds investment vehicles valued using nav provided fund administratorassets level category quoted market price assets assets represented primarily limited partnerships investment vehicles valued using nav provided fund administrator assets exchange listed actively traded classified level inactively traded assets classified level following table sets forth retirement plans ' investments measured fair value december december quoted prices significant active significant investments markets observable unobservable measured net identical assets inputs inputs asset value level level level total assets dollars millions shortterm investment funds government agency securities debt instruments equity securities commingled funds assets investments fair value activity level assets significant years presented company 's benefit plans unfunded except us commingled funds level million million december december respectively fair value johnson johnson common stock directly held plan assets million total plan assets december million total plan assets december savings plan company voluntary k savings plans designed enhance existing retirement programs covering eligible employees company matches percentage employees contributions consistent provisions plan heshe eligible total company matching contributions plans million million million fiscal years respectively capital treasury stock changes treasury stock treasury stock amounts millions except treasury stock shares thousands shares amount balance december employee compensation stock option plans repurchase common stock balance december employee compensation stock option plans repurchase common stock balance january employee compensation stock option plans repurchase common stock balance january aggregate shares common stock issued approximately shares end fiscal years cash dividends paid per share fiscal year compared dividends per share fiscal year per share fiscal year january board directors declared regular cash dividend per share payable march shareholders record february december company announced board directors approved share repurchase program authorizing company purchase billion company 's shares common stock share repurchase program completed september accumulated comprehensive income loss components comprehensive income loss consist following total gain accumulated foreign loss currency gainloss employee derivatives comprehensive dollars millions translation securities benefit plans hedges income loss december net changes december net changes january net changes january amounts accumulated comprehensive income presented net related tax impact foreign currency translation adjusted income taxes relates permanent investments international subsidiaries additional details comprehensive income see consolidated statements comprehensive income details reclassifications accumulated comprehensive income gainloss securities reclassifications released income expense net employee benefit plans reclassifications included net periodic benefit cost see note additional details gainloss derivatives hedges reclassifications earnings recorded account hedgedtransaction see note additional details international currency translation translation subsidiaries operating nonus dollar currencies company determined local currencies international subsidiaries functional currencies except highly inflationary economies defined compound cumulative rates inflation past three years substantial portion cash flows local currency majority company 's subsidiaries local currency functional currency consolidating international subsidiaries balance sheet currency effects recorded component accumulated comprehensive income current noncurrent assets line within statement cash flows includes impact foreign currency translation equity account includes results translating certain balance sheet assets liabilities current exchange rates accounts historical rates except located highly inflationary economies argentina venezuela translation balance sheet accounts highly inflationary economies reflected operating results rollforward changes fiscal years foreign currency translation adjustments included note net currency transaction gains losses included income expense losses million million million fiscal years respectively earnings per share following reconciliation basic net earnings per share diluted net earnings per share fiscal years ended january january december millions except per share amounts basic net earnings per share average shares outstanding basic potential shares exercisable stock option plans less shares repurchased treasury stock method convertible debt shares adjusted average shares outstanding diluted diluted net earnings per share diluted net earnings per share calculation fiscal year included shares related stock options exercise price options less average market value company 's stock january company convertible debt diluted net earnings per share calculation fiscal year excluded million shares related stock options exercise price options greater average market value company 's stock january company convertible debt diluted net earnings per share calculation fiscal year excluded insignificant number shares related stock options exercise price options greater average market value companys stock diluted net earnings per share calculation fiscal year included dilutive effect convertible debt offset related reduction interest expense million aftertax common stock stock option plans stock compensation agreements january company stockbased compensation plans shares outstanding contracts company 's longterm incentive plan longterm incentive plan longterm incentive plan expired april options restricted shares granted subsequent date longterm incentive plan longterm incentive plan company may issue million shares common stock plus shares canceled expired forfeited issued longterm incentive plan subsequent april shares available future grants longterm incentive plan million end fiscal year compensation cost charged income plans million million million fiscal years respectively total income tax benefit recognized income statementfor sharebased compensation costs million million million fiscal years respectively company also recognized additional income tax benefits million million million fiscal years respectively options exercised restricted shares vested total unrecognized compensation cost million million million fiscal years respectively weighted average period cost recognized years years years fiscal years respectively sharebased compensation costs capitalized part inventory insignificant periods company settles employee benefit equity issuances treasury shares treasury shares replenished market purchases throughout year number shares used settle employee benefit equity issuances stock options stock options expire years date grant vest service periods range months years options granted average high low prices companys common stock new york stock exchange date grant fair value option award estimated date grant using blackscholes option valuation model uses assumptions noted following table grants expected volatility represents blended rate year weekly historical overall volatility rate week average implied volatility rate based atthemoney traded johnson johnson options life years grants historical data used determine expected life option riskfree rate based us treasury yield curve effect time grant average fair value options granted fiscal years respectively fair value estimated based weighted average assumptions riskfree rate expected volatility expected life years expected dividend yield summary option activity plan january january december changes years ending dates presented aggregate weighted intrinsic outstanding average exercise value shares thousands shares price dollars millions shares december options granted options exercised options canceledforfeited shares december options granted options exercised options canceledforfeited shares january options granted options exercised options canceledforfeited shares january total intrinsic value options exercised million million million fiscal years respectively following table summarizes stock options outstanding exercisable january outstanding exercisable shares thousands weighted weighted average average exercise price range options average life exercise price options exercise price average contractual life remaining years stock options outstanding january december average life years average life years respectively stock options exercisable january december average price average price respectively restricted share units performance share units company grants restricted share units vest service periods range months years company also grants performance share units paid shares johnson johnson common stock end threeyear performance period whether performance share units vest amount vest tied completion service periods range months years achievement threeyear period three equallyweighted goals directly align help drive longterm total shareholder return operational sales adjusted operational earnings per share relative total shareholder return beginning fiscal performance shares granted two equallyweighted goals directly align help drive longterm total shareholder return adjusted operational earnings per share relative total shareholder return number shares actually earned end threeyear period vary based actual performance target number performance share units granted summary restricted share units performance share units activity plans january presented outstanding outstanding restricted share performance share units units shares thousands shares january granted issued canceledforfeitedadjusted shares january average fair value restricted share units granted fiscal years respectively using fair market value date grant fair value restricted share units discounted dividends paid restricted share units vesting period fair value restricted share units issued million million million respectively weighted average fair value performance share units granted fiscal years calculated using weighted average fair market value component goals date grant fair values sales earnings per share goals performance share unit estimated date grant using fair market value shares time award discounted dividends paid performance share units vesting period fair value relative total shareholder return goal performance share unit estimated date grant using monte carlo valuation model fair value performance share units issued million million million fiscal years respectively segments business geographic areas sales customers change dollars millions vs vs consumer health otc us international worldwide skin healthbeauty us international worldwide oral care us international worldwide baby care us international worldwide women 's health us international worldwide wound careother us international worldwide total consumer health us international worldwide pharmaceutical immunology us international worldwide remicade us us exports international worldwide simponi simponi aria us international worldwide stelara us international worldwide tremfya us international worldwide immunology us international worldwide infectious diseases us international worldwide covid vaccine us international worldwide edurant rilpivirine us international worldwide prezista prezcobix rezolsta symtuza us international worldwide infectious diseases us international worldwide neuroscience us international worldwide concerta methylphenidate us international worldwide invega sustenna xeplion invega trinza trevicta us international worldwide risperdal consta us international worldwide neuroscience us international worldwide oncology us international worldwide darzalex us international worldwide erleada us international worldwide imbruvica us international worldwide zytiga abiraterone acetate us international worldwide oncology us international worldwide pulmonary hypertension us international worldwide opsumit us international worldwide uptravi us international worldwide us international worldwide cardiovascular metabolism us international worldwide xarelto us international worldwide invokana invokamet us international worldwide procrit eprex us international worldwide us international worldwide total pharmaceutical us international worldwide medical devices interventional solutions us international worldwide orthopaedics us international worldwide hips us international worldwide knees us international worldwide trauma us international worldwide spine sports us international worldwide surgery us international worldwide advanced us international worldwide general us international worldwide vision us international worldwide contact lenses us international worldwide surgical us international worldwide total medical devices us international worldwide worldwide us international worldwide certain prior year amounts reclassified conform current year presentation percentage greater meaningful income loss tax identifiable assets dollars millions consumer health pharmaceutical medical devices total less expense allocated segments general corporate worldwide total additions property depreciation plant equipment amortization dollars millions consumer health pharmaceutical medical devices segments total general corporate worldwide total sales customers longlived assets dollars millions united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total see note description segments company operates export sales significant fiscal year company utilized three wholesalers distributing products three segments represented approximately total consolidated revenues fiscal year company three wholesalers distributing products three segments represented approximately total consolidated revenues fiscal year company three wholesalers distributing products three segments represented approximately total consolidated revenues amounts allocated segments include interest income expense general corporate income expense general corporate includes cash cash equivalents marketable securities consumer health includes litigation expense billion primarily talc related reserves restructuring related charge billion pharmaceutical includes litigation expense billion primarily related risperdal divestiture gains billion gains securities billion restructuring related charge billion medical devices includes restructuring related charge billion inprocess research development expense billion medical device regulation charge billion litigation expense billion consumer health includes litigation expense billion primarily talc related reserves certain settlements pharmaceutical includes litigation expense billion primarily related agreement principle settle opioid litigation unrealized gain securities billion restructuring related charge billion medical devices includes contingent consideration reversal billion related timing certain developmental milestones associated auris health acquisition litigation expense billion restructuring related charge billion inprocess research development expense billion medical device regulation charge billion consumer health includes gain billion related company 's previously held equity investment dr cilabo litigation expense billion restructuring related charge billion pharmaceutical includes litigation expense billion billion related agreement principle settle opioid litigation inprocess research development expense billion related alios asset research development expense billion upfront payment related argenx unrealized gain securities billion actelion acquisition integration related costs billion restructuring charge billion medical devices includes gain billion divestiture asp business restructuring related charge billion litigation expense billion auris health acquisition integration related costs billion longlived assets include property plant equipment net fiscal years respectively intangible assets goodwill net fiscal years respectively acquisitions divestitures fiscal year company make material acquisitions fiscal year certain businesses acquired billion cash billion liabilities assumed acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition excess purchase price estimated fair value tangible assets acquired amounted billion assigned identifiable intangible assets residual recorded goodwill fiscal year acquisitions primarily included rights investigational compound bermekimab multiple dermatological indications along certain employees xbiotech inc xbiotech momenta pharmaceuticals inc momenta company discovers develops novel therapies immunemediated diseases outstanding shares verb surgical inc company significant robotics data science capabilities fiscal first quarter company completed acquisition rights investigational compound bermekimab multiple dermatological indications along certain employees xbiotech inc purchase price billion fair value acquisition allocated primarily nonamortizable intangible assets primarily iprd billion applying probability success factor ranged reflect inherent development regulatory commercial risk different indications discount rate applied approximately xbiotech may eligible receive additional payments upon receipt certain commercialization authorizations transaction accounted business combination included pharmaceutical segment january subsequent fiscal year additional information regarding efficacy became available led company decision terminate development bermekimab atopic dermatitis ad company recorded intangible asset impairment charge approximately billion related inprocess research development asset bermekimab jnj investigational drug treatment ad hidradenitis suppurativa hs impairment charge related ad indication nonrecognized subsequent event reflected first quarter financial statements company acquired rights bermekimab xbiotech inc fiscal year additionally fiscal first quarter company completed acquisition outstanding shares verb surgical inc company significant robotics data science capabilities including shares previously held verily transaction accounted business combination included medical devices segment fair value acquisition allocated primarily nonamortizable intangible assets primarily iprd billion goodwill billion assets billion liabilities assumed billion fair value company 's previously held equity investment verb surgical inc billion october company completed acquisition momenta purchase price approximately billion net cash acquired fair value acquisition allocated primarily nonamortizable intangible assets iprd billion goodwill billion assets billion liabilities billion assets acquired intended address substantial unmet medical need maternalfetal disorders neuroinflammatory disorders rheumatology dermatology autoimmune hematology depending asset probability success factors ranging used fair value calculation reflect inherent development regulatory risk iprd discount rate applied approximately goodwill primarily attributable synergies expected arise business acquisition expected deductible tax purposes transaction accounted business combination included pharmaceutical segment fiscal year certain businesses acquired billion cash billion liabilities assumed acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition excess purchase price estimated fair value tangible assets acquired amounted billion hasbeen assigned identifiable intangible assets residual recorded goodwill fiscal year acquisitions primarily included dr cilabo japanese company focused marketing development distribution broad range dermocosmetic cosmetic skincare products auris health inc privately held developer robotic technologies initially focused lung cancer us fdacleared platform currently used bronchoscopic diagnostic therapeutic procedures january company acquired dr cilabo japanese company focused marketing development distribution broad range dermocosmetic cosmetic skincare products total purchase price approximately billion equates approximately billion using exchange rate japanese yen us dollar january additionally fiscal first quarter company recognized pretax gain recorded income expense net approximately billion related company 's previously held equity investment dr cilabo company treated transaction business combination included consumer health segment fiscal first quarter company finalized purchase price allocation final fair value acquisition allocated primarily amortizable intangible assets billion goodwill billion liabilities billion amortizable intangible assets comprised brandtrademarks customer relationships weighted average life years goodwill primarily attributable synergies expected arise business acquisition expected deductible tax purposes april company completed acquisition auris health inc approximately billion net cash acquired additional contingent payments billion aggregate may payable upon reaching certain predetermined milestones auris health privately held developer robotic technologies initially focused lung cancer us fdacleared platform currently used bronchoscopic diagnostic therapeutic procedures company treated transaction business combination included medical devices segment fair value acquisition allocated primarily amortizable nonamortizable intangible assets primarily iprd billion goodwill billion marketable securities billion liabilities assumed billion includes fair value contingent payments mentioned goodwill primarily attributable synergies expected arise business acquisition expected deductible tax purposes fiscal second quarter company finalized purchase price allocation fiscal company recorded income approximately billion reversal contingent consideration related timing certain developmental commercial milestones expected met based companys current timelines fiscal third quarter company recorded partial iprd impairment charge billion related timing progression digital surgery platforms fiscal third quarter company recorded partial iprd charge billion primarily related expected development delays general surgery digital robotics platform ottava probability success factor ranging across ottava subplatforms used fair value calculation reflect inherent regulatory commercial risk contingent payments iprd discount rate applied approximately accordance us gaap standards related business combinations goodwill intangible assets supplemental pro forma information fiscal years provided impact aforementioned acquisitions material effect companys results operations cash flows financial position divestitures fiscal year separate transactions company divested two brands outside us within pharmaceutical segment company recognized pretax gain recorded income expense net approximately billion fiscal year company sold million shares idorsia ltd idorsia ownership company time transaction resulted gross proceeds approximately chf million million based sales price chf share resulted immaterial net loss end fiscal company rights approximately million shares convertible loan principal amount chf million due june fiscal year company converted chf million million loan approximately million shares idorsia reflected fair value january fiscal third quarter company 's undrawn credit facility idorsia terminated fiscal year company divested asp business fortive corporation aggregate value approximately billion consisting billion cash proceeds billion retained net receivables company recognized pretax gain recorded income expense net approximately billion legal proceedings johnson johnson certain subsidiaries involved various lawsuits claims regarding product liability intellectual property commercial indemnification matters governmental investigations legal proceedings arise time time ordinary course business due ongoing impacts covid pandemic certain trials rescheduled delayed company continues monitor legal proceedings situationevolves person trials resume company records accruals loss contingencies associated legal matters probable liability incurred amount loss reasonably estimated january company determined liabilities associated certain litigation matters probable reasonably estimated company accrued matters continue monitor related legal issue adjust accruals might warranted based new information developments accordance asc litigation regulatory matters discussed loss probable reasonably possible company unable estimate possible loss range loss beyond amounts accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions including timing related payments ability make estimates judgments affected various factors including among things whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute procedural jurisdictional issues uncertainty unpredictability number potential claims ability achieve comprehensive multiparty settlements complexity related crossclaims counterclaims andor numerous parties involved extent adverse awards judgments verdicts rendered company company record accrual loss determined probable reasonably estimated companys opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued companys balance sheet expected material adverse effect companys financial position however resolution increase accruals one matters reporting period may material adverse effect companys results operations cash flows period product liability johnson johnson certain subsidiaries involved numerous product liability claims lawsuits involving multiple products claimants cases seek substantial compensatory available punitive damages company believes substantial defenses feasible predict ultimate outcome litigation time time even substantial defenses company considers isolated settlements based variety circumstances company established accruals product liability claims lawsuits compliance asc based currently available information cases may limited company accrues estimate legal defense costs needed defend matter costs probable reasonably estimated certain matters company accrued additional amounts estimated costs associated settlements damages losses product liability accruals represent projected product liability thousands claims around world different litigation environments different fact patterns changes accruals may required future additional information becomes available significant cases include depuy asr xl acetabular system depuy asr hip resurfacing system pinnacle acetabular cup system pelvic meshes risperdal xarelto body powders containing talc primarily johnson 's baby powder invokana ethicon physiomesh flexible composite mesh january united states approximately plaintiffs direct claims pending lawsuits regarding injuries allegedly due depuy asr xl acetabular system depuy asr hip resurfacing system respect pinnacle acetabular cup system respect pelvic meshes respect risperdal respect xarelto respect body powders containing talc respect invokana respect ethicon physiomesh flexible composite mesh number pending lawsuits expected fluctuate certain lawsuits settled dismissed additional lawsuits filed august depuy orthopaedics inc depuy announced worldwide voluntary recall asr x l acetabular system depuy asr h ip resurfacing system asr hip used hip replacement surgery claims personal injury made depuy johnson johnson cases filed federal courts united states organized multidistrict litigation united states district court northern district ohio litigation also filed countries outside united states primarily united kingdom canada australia ireland germany india italy november depuy reached agreement courtappointed committee lawyers representing asr hip plaintiffs establish program settle claims eligible asr hip patients united states surgery replace asr hips known revision surgery august depuy reached additional agreements february march extended settlement program include asr hip patients revision surgeries august prior february settlement program resolved claims thereby bringing resolutionsignificant asr hip litigation activity united states however lawsuits united states remain settlement program address litigation outside united states australia class action settlement reached resolved claims majority asr hip patients country canada company reached agreements settle class actions filed country company continues receive information respect potential additional costs associated recall worldwide basis company established accruals costs associated united states settlement program asr hiprelated product liability litigation claims personal injury also made depuy orthopaedics inc johnson johnson collectively depuy relating pinnacle acetabular cup system used hip replacement surgery product liability lawsuits continue filed company continues receive information respect potential costs anticipated number cases cases filed federal courts united states organized multidistrict litigation united states district court northern district texas litigation also filed state courts countries outside united states several adverse verdicts rendered depuy one reversed appeal remanded retrial first quarter depuy established united states settlement program resolve cases part settlement program adverse verdicts settled company established accrual product liability litigation associated pinnacle acetabular cup system related settlement program claims personal injury made ethicon inc ethicon johnson johnson arising ethicons pelvic mesh devices used treat stress urinary incontinence pelvic organ prolapse company continues receive information respect potential costs additional cases cases filed federal courts united states organized multidistrict litigation mdl united states district court southern district west virginia march mdl court entered order closing mdl mdl court remanded cases trial jurisdictions case originally filed additional pelvic mesh lawsuits filed remain outside mdl company settled otherwise resolved majority united states cases estimated costs associated settlements remaining cases reflected companys accruals addition class actions individual personal injury cases claims seeking damages alleged injury resulting ethicons pelvic mesh devices commenced various countries outside united states including claims cases united kingdom netherlands class actions israel australia canada november federal court australia issued judgment regarding findings respect liability relation three lead applicants generally relation design manufacture pre postmarket assessments testing supply promotion devices australia used treat stress urinary incontinence pelvic organ prolapse march court issued decision entered damages awards three lead applicants company appealed decision intermediate appellate court full court appeal heard february march full court entered judgment dismissing appeal application special leave high court australia filed april high court heard oral argument application november special leave refused brings end appellate process individual case assessment process remaining group member claims parties currently discussions court determine form mechanism individual case assessment process next hearing scheduled late february class actions canada discontinued result settlement group cases agreement resolve israeli class action reached may parties israeli class action currently negotiating wording terms thereof finalized settlement subject court approval parties due update court status finalization settlement negotiations end february company established accruals respect product liability litigation associated ethicons pelvic mesh products following june worldwide market withdrawal ethicon physiomesh flexible composite mesh physiomesh claims personal injury made ethicon inc ethicon johnson johnson alleging personal injury arising use hernia mesh device cases filed federal courts united states organized multidistrict litigation mdl united states district court northern district georgia multicounty litigation mcl also formed new jersey state court assigned atlantic county cases pending new jersey addition matters mdl mcl additional lawsuits pending united states district court southern district ohio part mdl polypropylene mesh devices manufactured cr bard inc one multiplaintiff lawsuit pending oklahoma state court lawsuits pending outside united states may ethicon lead counsel plaintiffs entered term sheet resolve approximately physiomesh cases covering approximately plaintiffs pending mdl mcl time master settlement agreement msa entered september includes cases mdl mcl deadlines trial settings proceedings currently stayed pending completion settlement agreement deadline issuance individual allocation amounts special master march costs associated proposed settlement reflected companys accruals postsettlement cases physiomesh mdl mcl subject docket control orders requiring early expert reports discovery requirements february approximately active cases subject orders reviewed evaluatedclaims also filed ethicon johnson johnson alleging personal injuries arising proceed mesh proceed ventral patch hernia mesh products march new jersey supreme court entered order consolidating cases pending new jersey mcl atlantic county superior court additional cases filed various federal state courts united states jurisdictions outside united states discovery underway mcl proceedings ethicon johnson johnson also subject claims personal injuries arising prolene polypropylene hernia system january new jersey supreme court created mcl atlantic county superior court handle cases cases involving product also filed federal state courts united states company established accruals respect product liability litigation associated ethicon physiomesh flexible composite mesh proceed mesh proceed ventral patch prolene polypropylene hernia system products claims personal injury made janssen pharmaceuticals inc johnson johnson arising use risperdal related compounds indicated treatment schizophrenia acute manic mixed episodes associated bipolar disorder irritability associated autism lawsuits primarily filed state courts pennsylvania california missouri actions pending various courts united states canada product liability lawsuits continue filed company continues receive information respect potential costs anticipated number cases company successfully defended number cases verdicts company including verdict october billion punitive damages related one plaintiff trial judge reduced million january september company entered settlement principle counsel representing plaintiffs matter substantially outstanding cases united states costs associated settlements reflected companys accruals claims personal injury arising use xarelto oral anticoagulant made janssen pharmaceuticals inc jpi johnson johnson jpis collaboration partner xarelto bayer healthcare ag certain affiliates cases filed federal courts united states organized multidistrict litigation united states district court eastern district louisiana addition cases filed state courts across united states many cases consolidated state mass tort litigation philadelphia pennsylvania coordinated proceeding los angeles california class action lawsuits also filed canada march jpi johnson johnson announced agreement principle settle xarelto cases united states settlement agreement executed may settlement became final december settlement funded january resolved majority cases pending united states company established accruals costs associated united states settlement program xarelto related product liability litigation significant number personal injury claims alleging talc causes cancer made johnson johnson consumer inc johnson johnson arising use body powders containing talc primarily johnsons baby powder number personal injury lawsuits filed state federal courts united states well outside united states continued increase fiscal year talc cases previously gone trial company obtained number defense verdicts also verdicts company many reversed appeal june missouri court appeals reversed part affirmed part july verdict billion ingham v johnson johnson et al ed mo app reducing overall award billion application transfer case missouri supreme court subsequently denied june petition certiorari seeking review ingham decision united states supreme court denied june company paid award including interest totaled approximately billion facts circumstances including terms award unique ingham decision representative claims brought company company continues believe strong legal grounds contest talc verdicts appealed notwithstanding companys confidence safety talc products certain circumstances company settled cases october johnson johnson consumer inc old jjci implemented corporate restructuring corporate restructuring result restructuring old jjci ceased exist three new entities created ltl management llc north carolina limited liability company ltl debtor b royalty llc north carolina limited liability company direct subsidiary ltl ram c debtors direct parent johnson johnson consumer inc new jersey company new jjci debtor received certain old jjcis assets became solely responsible talcrelated liabilities old jjci including liabilities related way injury damage alleged injury damage sustained incurred purchase use exposure talc including talc contained product risk responsibility damage injury except liabilities exclusive remedy isprovided workers compensation statute act talcrelated liabilities october notwithstanding companys confidence safety talc products debtor filed voluntary petition united states bankruptcy court western district north carolina charlotte division seeking relief chapter bankruptcy code ltl bankruptcy case result ltl bankruptcy case court entered temporary restraining order staying litigation ltl old jjci november north carolina bankruptcy court confirmed scope stay issuing preliminary injunction pi prohibiting enjoining commencement prosecution talcrelated claims ltl old jjci new jjci johnson johnson corporate affiliates identified retailers insurance companies certain parties ltl bankruptcy case transferred united states bankruptcy court district new jersey november court subsequently extended pi end february claimants filed motion dismiss ltl bankruptcy case court commenced hearing february regarding motion dismiss whether pi extended pi effectively stays companys talcrelated personal injury litigation ltl agreed lift automatic stay small number appeals appeal bonds filed company agreed provide funding ltl payment amounts bankruptcy court determines owed ltl establishment billion trust furtherance purpose company established reserve approximately billion connection aforementioned trust subsequent fiscal third quarter company deconsolidated ltl related party result bankruptcy filing impact deconsolidation material company parties yet able reach resolution matters related talc certain amounts various scenarios recently referred testimony part ltl bankruptcy proceedings company unable estimate possible loss range loss beyond amount accrued february companys talc supplier imerys talc america inc two affiliates imerys talc vermont inc imerys talc canada inc collectively imerys filed voluntary petition chapter united states code bankruptcy code united states bankruptcy court district delaware imerys bankruptcy imerys bankruptcy relates imeryss potential liability personal injury exposure talcum powder sold imerys talc claims bankruptcy imerys alleges claims company indemnification rights joint insurance proceeds may imerys parent imerys sa tort claimants committee tcc future claimants representative fcr collectively plan proponents filed plan reorganization plan disclosure statement related thereto plan proponents since filed numerous amendments plan disclosure statement hearing plan proponents disclosure statement held january court entered order approving disclosure statement allowing imerys proceed soliciting votes plan march company voted reject plan opted consensual releases plan april plan proponents announced plan received requisite number accepting votes confirm plan company challenged certain improprieties respect portions vote sought disqualify votes october bankruptcy court issued ruling deeming thousands votes withdrawn improperly voted october imerys cancelled confirmation hearing plan imerys tcc fcr certain imeryss insurers mediation parties since agreed engage mediation july imerys commenced adversary proceeding company imerys bankruptcy imerys adversary proceeding imerys adversary proceeding sought among things certain declarations respect indemnification obligations allegedly owed company imerys tcc fcr simultaneously filed motion temporary restraining order preliminary injunction seeking enjoin company undergoing corporate restructuring would separate companys talc liabilities assets bankruptcy court denied motion company thereafter filed motion dismiss adversary proceeding bankruptcy court yet decided motion dismiss october company filed notice bankruptcy filing stay proceedings clarifying automatic stay arising upon filing ltl bankruptcy case apply imerys adversary proceeding june cyprus mines corporation parent together cyprus owned certain imerys talc mines filed adversary proceeding company imerys imerys bankruptcy seeking declaration indemnity rights certain contractual agreements cyprus adversary proceeding company denies indemnification owed filed motion dismiss adversary complaint february cyprus filed voluntary petition relief chapter bankruptcy code filed disclosure statement plan plan contemplates settlement imerys talc claimants cyprus would make monetary contribution trust established imerys plan exchange injunction talc claims asserted cyprus yet sought approval disclosure statement plan cyprus along tcc fcr appointed cyprus chapter case agreed participate mediation mediation parties october company filed notice bankruptcy filing stay proceedings clarifying automatic stay arising upon filing ltl bankruptcy case apply cyprus adversary proceeding february several companys insurers involved coverage litigation new jersey state court coverage action filed motion imerys bankruptcy court proceeding seeking determination automatic stay apply coverage action alternative seeking relief automatic stay allow continue litigatetheir claims coverage action march company filed limited response reservation rights respect motion court entered agreed order modifying stay allow litigation coverage action continue october ltl filed notice bankruptcy filing stay proceedings clarifying automatic stay arising upon filing ltl bankruptcy case apply coverage action february securities class action lawsuit filed johnson johnson certain named officers united states district court district new jersey alleging johnson johnson violated federal securities laws failing disclose alleged asbestos contamination body powders containing talc primarily johnsons baby powder purchasers johnson johnsons shares suffered losses result plaintiff seeking damages april company moved dismiss complaint briefing motion complete august december court denied part motion dismiss march company answered complaint april briefing plaintiffs motion class certification completed july company filed notice supplemental authority opposition plaintiffs motion class certification plaintiff filed response december company filed motion supplement class certification record january plaintiff responded discovery ongoing june shareholder filed complaint initiating summary proceeding new jersey state court books records inspection august johnson johnson responded books records complaint filed cross motion dismiss september plaintiff replied court heard oral argument february court granted johnson johnson 's cross motion dismiss october december january four shareholders filed four separate derivative lawsuits johnson johnson nominal defendant current directors certain officers defendants united states district court district new jersey alleging breach fiduciary duties related alleged asbestos contamination body powders containing talc primarily johnsons baby powder johnson johnson suffered damages result alleged breaches february four cases consolidated single action caption johnson johnson talc stockholder derivative litigation july report delivered companys board directors independent counsel retained board investigate allegations derivative lawsuits series shareholder letters board received raising similar issues demanding suit brought certain directors four shareholders sent demands plaintiffs th e johnson johnson talc stockholder derivative litigation independent counsel recommended company reject shareholder demands take steps necessary appropriate secure dismissal derivative lawsuits board unanimously adopted recommendations independent counsels report october shareholders filed consolidated complaint january johnson johnson moved dismiss consolidated complaint march plaintiffs filed motion discovery court temporarily terminated johnson johnsons motion dismiss pending decision plaintiffs motion discovery november courts request parties submitted supplemental briefing plaintiffs motion discovery january two erisa class action lawsuits filed participants johnson johnson savings plan johnson johnson pension benefits committee certain named officers united states district court district new jersey alleging defendants breached fiduciary duties offering johnson johnson stock johnson johnson savings plan investment option imprudent failures disclose alleged asbestos contamination body powders containing talc primarily johnsons baby powder plaintiffs seeking damages injunctive relief september defendants filed motion dismiss april court granted defendants motion granted leave amend june plaintiffs filed amended complaint july defendants moved dismiss amended complaint october briefing defendants motion complete february court granted defendants motion granted plaintiffs leave amend april plaintiffs informed court intend file amended complaint court dismissed case prejudice may plaintiffs filed notice appeal third circuit july plaintiffs filed opening brief third circuit september defendants filed response brief october plaintiffs filed reply brief january third circuit heard oral argument lawsuit brought company superior court california county san diego alleging violations californias consumer legal remedies act clra relating johnsons baby powder lawsuit plaintiffs allege johnson johnson violated clra failing provide required proposition warnings july company filed notice removal united states district court southern district california plaintiffs filed second amended complaint shortly thereafter october company moved dismiss second amended complaint failure state claim upon relief may granted response motions plaintiffs filed third amended complaint december company moved dismiss third amended complaint failure state claim upon relief may granted april court granted motion dismiss granted leave amend may plaintiffs filed fourth amended complaint indicated would filing motion leave file fifth amended complaint plaintiffs filed fifth amended complaint august company moved dismiss fifth amended complaint failure state claim upon relief may granted january court issued order opinion ruling companys favor granting motion dismiss prejudice february plaintiffs filed notice appeal ninth circuit plaintiffs filed opening brief july company filed responsive brief october october notice suggestion bankruptcy filed ninth circuit bankruptcy stay imposed december court held reply deadline abeyancein addition company received inquiries subpoenas requests produce documents regarding talc matters including senator murray member senate committee health education labor pensions department justice subcommittee economic consumer policy house committee oversight reform senate committee judiciary house committee oversight reform individual members congress company produced documents responded inquiries continue cooperate government inquiries claims personal injury made number johnson johnson companies including janssen pharmaceuticals inc johnson johnson arising use invokana prescription medication indicated improve glycemic control adults type diabetes december lawsuits filed federal courts united states organized multidistrict litigation united states district court district new jersey cases also filed state courts class action lawsuits filed canada product liability lawsuits continue filed company continues receive information respect potential costs anticipated number cases company settled otherwise resolved many cases claims united states costs associated settlements reflected companys accruals claims personal injury made number johnson johnson companies including janssen pharmaceuticals inc johnson johnson arising use elmiron prescription medication indicated relief bladder pain discomfort associated interstitial cystitis lawsuits allege elmiron contributes development permanent retinal injury vision loss filed state federal courts across united states december lawsuits filed federal courts united states including putative class action cases seeking medical monitoring organized multidistrict litigation united states district court district new jersey cases also filed various state courts addition three class action lawsuits filed canada product liability lawsuits continue filed company continues receive information respect potential costs anticipated number cases company established accruals defense costs associated elmiron related product liability litigation intellectual property certain subsidiaries johnson johnson subject time time legal proceedings claims related patent trademark intellectual property matters arising businesses many matters involve challenges coverage andor validity patents various products allegations certain companys products infringe patents third parties although subsidiaries believe substantial defenses challenges allegations respect significant patents assurance outcome matters loss cases could adversely affect ability subsidiaries sell products result loss sales due loss market exclusivity require payment past damages future royalties may result noncash impairment charge associated intangible asset significant matters described medical devices december dr ford albritton sued acclarent inc acclarent united states district court northern district texas alleging acclarents relieva spin relievea spinplus products infringe us patent dr albritton also alleges breach contract fraud true owner acclarents us patent trial began october shortly thereafter parties reached agreement settle case plaintiffs motion dismiss prejudice filed october case dismissed prejudice november august intuitive surgical inc intuitive surgical operations inc collectively intuitive filed patent infringement suit auris health inc auris united states district court district delaware suit intuitive alleges willful infringement us patent nos based auris monarch platform auris filed ipr petitions us patent trademark office uspto regarding patents intuitive subsequently dropped patents suit december uspto instituted review patent denied review patent february march uspto instituted review patents denied review patent december uspto declared challenged claims patent invalid intuitive appealed decision march uspto ruled challenged claims patents invalid auris appealed decision auris filed request reexamination patent november january uspto granted reexamination request trial scheduled begin january august rsb spine llc rsb spine filed patent infringement suit depuy synthes inc united states district court district delaware october rsb spine amended complaint change named defendants depuy synthes sales inc depuy synthes products inc suit rsb spine alleges willful infringement united states patent nos one following products zeropva spacer zerop spacer zerop natural plate synfix lr spacer synfix evolution system rsb spine seeks monetary damages injunctive relief november suit consolidated pretrial purposes patent infringement suits brought rsb spine united states district court district delaware life spine inc medacta usa inc precision spine inc stay entered pending inter partes review us patent trademark office lifted trial scheduled begin december march osteoplastics llc filed patent infringement suit depuy synthes inc depuy synthes products inc medical device business services inc synthes inc collectively depuy synthes united states district court district delaware suit osteoplastics alleges willful infringement us patent nos based proplan cmf virtual surgical planning services trumatch cmf personalize solutions april osteoplastics filed amended complaint substitute us patent us patent osteoplastics seeks monetary damages injunctive relief june depuy synthes filed motion dismiss complaint october court dismissed medical device business services inc case otherwise denied motion june osteoplastics admitted proplan cmf virtual surgical planning services infringe asserted patents trial scheduled october october case settled dismissed october rasmussen instruments llc rasmussen filed patent infringement suit depuy synthes products inc depuy synthes sales inc medical device business services inc collectively depuy united states district court district massachusetts rasmussen alleges depuy willfully infringes us patent nos making selling attune balanced sizer april rasmussen sought permission amend infringement contentions allege depuy also willfully infringes patent making selling attune balancing blocks rasmussen seeks treble damages willful infringement trial scheduled february pharmaceutical litigation filers abbreviated new drug applications andas following summarizes lawsuits companys subsidiaries brought generic companies filed andas us fda undertaken similar regulatory processes outside united states seeking market generic forms products sold various subsidiaries johnson johnson prior expiration applicable patents covering products andas typically include allegations noninfringement invalidity applicable patents event companys subsidiaries successful action automatic statutory stay andas expires united states district court rulings obtained generic companies involved would ability upon approval us fda introduce generic versions products market resulting potential substantial market share revenue losses applicable products may result noncash impairment charge associated intangible asset addition time time companys subsidiaries may settle types actions settlements involve introduction generic versions products issue market prior expiration relevant patents inter partes review ipr process uspto created america invents act also used times generic companies conjunction andas lawsuits challenge applicable patents zytiga beginning january janssen inc janssen oncology inc collectively janssen initiated statements claim section patented medicines notice compliance regulations canada apotex inc apotex pharmascience inc pharmascience dr reddys laboratories ltd dr reddys laboratories inc collectively drl response parties filing abbreviated new drug submissions ands seeking approval market generic versions zytiga expiration canadian patent trial actions concluded november court issued decision holding patent invalid january february janssen appealed decision xarelto march janssen pharmaceuticals inc jpi bayer pharma ag bayer ag collectively bayer filed patent infringement lawsuit united states district court district delaware lupin limited lupin pharmaceuticals inc filed anda seeking approval market generic version xarelto expiration us patent may jpi bayer filed patent infringement lawsuit united states district court district delaware dr reddys laboratories inc dr reddys laboratories ltd filed anda seeking approval market generic version xarelto expiration patent july jpi bayer filed patent infringement lawsuit united states district court district delaware taro pharmaceutical industries ltd taro pharmaceuticals usa inc collectively taro filed anda seeking approval market generic version xarelto expiration patent july jpi bayer filed patent infringement lawsuit united states district court district delaware teva pharmaceuticals usa inc teva pharmaceutical industries ltd filed anda seeking approval market generic version xarelto expiration patent august court entered joint stipulation dismissing teva pharmaceutical industries ltd october court consolidated delaware lawsuits purposes including trial trial consolidated delaware lawsuits scheduled begin may july jpi bayer filed patent infringement lawsuit united states district court northern district west virginia mylan pharmaceuticals inc mylan inc filed anda seeking approval market generic version xarelto expiration patent august jpi bayer filed motion united states judicial panel multidistrict litigation mdl panel transfer lawsuit united states district court district delaware coordinated consolidated pretrial proceedings december mdl panel granted motion trial date set lawsuit lawsuits jpi bayer seeking order enjoining defendants marketing generic version xarelto expiration patent invokana invokamet invokamet xr october janssen pharmaceuticals inc janssen research development llc cilag gmbh international janssen pharmaceutica nv collectively janssen mitsubishi tanabe pharma corporation mtpc initiated patent infringement lawsuit united states district court district new jersey dr reddys laboratories inc dr reddys laboratories ltd drl filed anda seeking approval market generic version invokamet expiration mtpcs united states patent relating invokamet january janssen mtpc filed patent infringement lawsuit united states district court district new jersey macleods pharmaceuticals ltd macleods pharma usa inc macleods filed anda seeking approval market generic version invokamet xr expiration mtpcs united states patent nos andor relating invokamet xr us lawsuits janssen mtpc seeking order enjoining defendant marketing generic versions invokamet andor invokamet xr expiration relevant patents october janssen inc janssen pharmaceutica nv mtpc initiated statement claim section patented medicines notice compliance regulations sandoz canada inc sandoz canada response sandozs filing ands seeking approval market generic version invokana expiration canadian patent nos janssen inc janssen pharmaceutica nv mtpc seeking order enjoining sandoz marketing generic version invokana expiration relevant patents trial scheduled begin august opsumit may janssen inc janssen actelion pharmaceuticals ltd actelion initiated statement claim section patented medicines notice compliance regulations sandoz canada inc sandoz canada response sandozs filing ands seeking approval market generic version opsumit mg expiration canadian patent trial ongoing may janssen actelion initiated statement claim section patented medicines notice compliance regulations apotex inc apotex canada response apotexs filing ands seeking approval market generic version opsumit mg expiration patent trial scheduled begin february july janssen actelion initiated statement claim section patented medicines notice compliance regulations jamp pharma corporation jamp canada response jamps filing ands seeking approval market generic version opsumit mg expiration patent canadian patent trial scheduled begin april canadian actions janssen actelion seeking order enjoining defendants marketing generic versions opsumit expiration relevant patents invega sustenna january janssen pharmaceutica nv janssen pharmaceuticals inc collectively janssen initiated patent infringement lawsuit united states district court district new jersey teva pharmaceuticals usa inc teva filed anda seeking approval market generic version invega sustenna expiration united states patent trial concluded october october court issued decision janssens favor teva appealed decision august janssen initiated patent infringement lawsuit united states district court district new jersey mylan laboratories limited mylan filed anda seeking approval market generic version invega sustenna expiration patent pursuant agreement parties judgment favor janssen entered december mylan filed appeal december janssen initiated patent infringement lawsuit united states district courts districts new jersey delaware pharmascience inc mallinckrodt plc specgx llc collectively pharmascience filed anda seeking approval market generic version invega sustenna expiration patent november janssen initiated patent infringement lawsuit united states district court district delaware tolmar inc tolmar therapeutics inc tolmar pharmaceuticals inc tolmar holding inc collectively tolmar filed anda seeking approval market generic version invega sustenna expiration patent us lawsuits janssen seeking order enjoining defendant marketing generic version invega sustenna expiration relevant patents february janssen inc janssen pharmaceutica nv collectively janssen canada initiated statement claim section patented medicines notice compliance regulations teva canada limited teva canada response tevas filing ands seeking approval market generic version invega sustenna expiration canadian patent nos janssen subsequently discontinued portion lawsuit relating patent may canadian federal court issued public judgment reasons declaring teva canadas generic version invega sustenna approved would infringe certain claims patent claims patent invalid obviousness teva canada appealed november janssen canada initiated statement claim section patented medicines notice compliance regulations pharmascience inc response pharmascience incs filing ands seeking approval market generic version invega sustenna expiration patent summary trial issue infringement took place november january court issued decision favor janssen issue infringement trial issue validity scheduled begin july january janssen canada initiated statement claim section patented medicines notice compliance regulations apotex inc apotex response apotexs filing ands seeking approval market generic version invega sustenna expiration patent summary trial issue infringement took place december january court issued decision favor janssen issue infringement apotex contested validity canadian lawsuits janssen canada seeking order enjoining defendant marketing generic version invega sustenna expiration relevant patents invega trinza september janssen pharmaceuticals inc janssen pharmaceutica nv janssen research development llccollectively janssen initiated patent infringement lawsuit united states district court district new jersey mylan laboratories limited mylan pharmaceuticals inc mylan institutional llc collectively mylan mylan filed anda seeking approval market generic versions invega trinza mg expiration united states patent relating invega trinza mg janssen seeking order enjoining mylan marketing generic version invega trinza expiration patent trial scheduled begin october august janssen initiated patent infringement lawsuit united states district court district new jersey mylan mylan filed anda seeking approval market generic versions invega trinza mg expiration patent janssen seeking order enjoining mylan marketing generic version invega trinza mg expiration patent october janssen initiated patent infringement lawsuit united states district court district new jersey mylan mylan filed anda seeking approval market generic versions invega trinza mg mg expiration patent janssen seeking order enjoining mylan marketing generic version invega trinza mg mg expiration patent january court consolidated three cases case filed september imbruvica march pharmacyclics llc pharmacyclics janssen biotech inc jbi filed patent infringement lawsuit united states district court district delaware alvogen pine brook llc natco pharma ltd collectively alvogen filed anda seeking approval market generic versions imbruvica tablets asserting infringement united states patent nos june pharmacyclics jbi amended complaint alvogen allege infringement united states patent pharmacyclics jbi seeking order enjoining defendants marketing generic versions imbruvica expiration relevant patents trial alvogen took place october august district court issued decision favor pharmacyclics janssen finding asserted claims alvogen infringed invalid alvogen appealed decision september pharmacyclics janssen inc janssen canada initiated statements claim section patented medicines notice compliance regulations natco pharma canada inc natco response natcos filing two andss seeking approval market generic versions imbruvica capsules expiration canadian patent nos trial scheduled begin july pharmacyclics janssen seeking order enjoining natco marketing generic versions imbruvica expiration relevant patents uptravi april actelion pharmaceuticals ltd actelion nippon shinyaku co ltd nippon shinyaku initiated patent infringement lawsuit united states district court district new jersey zydus pharmaceuticals usa inc zydus worldwide dmcc collectively zydus filed anda seeking approval market generic version uptravi expiration nippon shinyakus united states patent nos relating uptravi actelion exclusive licensee patent january actelion nippon shinyaku zydus entered confidential settlement agreement lawsuit dismissed government proceedings like companies pharmaceutical consumer health medical devices industries johnson johnson certain subsidiaries subject extensive regulation national state local government agencies united states countries operate regulation basis government investigations litigations significant litigation brought investigations conducted government agencies listed possible criminal charges substantial fines andor civil penalties damages could result government investigations litigation average wholesale price awp litigationjohnson johnson several pharmaceutical subsidiaries jj awp defendants along numerous pharmaceutical companies named defendants series lawsuits state federal courts involving allegations pricing marketing certain pharmaceutical products amounted fraudulent otherwise actionable conduct among things companies allegedly reported inflated average wholesale price awp drugs issue payors alleged used awps calculating provider reimbursement levels plaintiffs cases included three classes private persons entities paid portion purchase drugs issue based awp state government entities made medicaid payments drugs issue based awp many cases federal actions state actions removed federal court consolidated pretrial purposes multidistrict litigation united states district court district massachusetts claims jj awp defendants ultimately dismissed jj awp defendants also prevailed case brought commonwealth pennsylvania awp cases resolved court order settlement case brought illinois settled trial new jersey putative class action based upon awp allegations pending centocor inc ortho biotech inc janssen biotech inc johnson johnson alza corporation cases resolved opioid litigation beginning continuing present johnson johnson janssen pharmaceuticals inc jpi along pharmaceutical companies named approximately lawsuits related marketing opioids including duragesic nucynta nucynta er suits also raise allegations related previously owned active pharmaceutical ingredient supplier subsidiaries tasmanian alkaloids pty ltd noramco inc subsidiaries divested majority cases filed state local governments similar lawsuits also filed private plaintiffs organizations including limited following individual plaintiffs behalf children suffering neonatal abstinence syndrome hospitals health insurerspayors date complaints pharmaceutical manufacturers including johnson johnson jpi filed state attorneys general arkansas florida idaho illinois kentucky louisiana mississippi missouri nevada new hampshire new jersey new mexico new york ohio oklahoma south dakota texas washington west virginia complaints manufacturers also filed state federal court city county local government agencies following states alabama arizona arkansas california colorado connecticut delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virginia washington west virginia wisconsin wyoming government puerto rico filed suit superior court san juan cases pending various state courts close federal cases coordinated federal multidistrict litigation mdl pending us district court northern district ohio addition province british columbia filed suit johnson johnson canadian affiliate janssen inc many industry members canada seeking action certified opt class action behalf provincialterritorial federal governments canada additional proposed class actions filed canada johnson johnson janssen inc many industry members behalf people used opioids personal injuries municipalities first nations bands october antitrust complaint filed private plaintiffs federal court tennessee pending transfer mdl actions allege variety claims related opioid marketing practices including false advertising unfair competition public nuisance consumer fraud violations deceptive acts practices false claims unjust enrichment suits generally seek penalties andor injunctive monetary relief suits plaintiffs seeking joint several liability among defendants adverse judgment lawsuits could result imposition large monetary penalties significant damages including punitive damages cost abatement substantial fines equitable remedies sanctions trial matter filed oklahoma attorney general resulted judgment johnson johnson jpi amount million johnson johnson jpi appealed judgment november oklahoma supreme court reversed trial courts judgment october johnson johnson jpi announced settlement first case set trial mdl two counties ohio april three california counties city oakland commenced trial california state court johnson johnson jpi affiliates well three pharmaceutical manufacturers trial concluded october december court entered final trial judgment favor defendants claims february plaintiffs ' motion set aside vacate judgment denied august johnson johnson received grand jury subpoena united states attorneys office eastern district new york documents related companys antidiversion policies procedures distribution opioid medications company understands part broader investigation manufacturers distributors monitoring programs reporting controlled substances act september johnson johnson received subpoenas new york state department financial services nydfs part industrywide inquiry effect opioid prescriptions new york health insurance premiums september company learned nydfs filed statement charges related investigation june company jpi announced settlement agreement state new york participatingsubdivisions including nassau county suffolk county resolving opioidrelated claims company terms consistent companys previously announced agreement principle contribute billion allin settlement opioidrelated claims states cities counties tribal governments settlement provides new york participating subdivisions million address opioidrelated issues reimburses attorney fees costs removes company janssen multidefendant trial opioidrelated claims commenced suffolk county june exchange company jpi receive releases claims asserted new york participating parties including nydfs october company jpi announced settlement agreement state texas participating subdivisions including dallas county bexar county tarrant county resolving opioidrelated claims company terms consistent companys previously announced agreement contribute billion allin settlement opioidrelated claims states cities counties tribal governments settlement provides texas participating subdivisions million address opioidrelated issues reimburse attorney fees costs removes company janssen multidefendant bellwether trials opioidrelated claims scheduled commence texas state courts early exchange company jpi receive releases claims asserted texas participating subdivisions johnson johnson jpi pharmaceutical companies also received subpoenas requests information related opioids marketing practices following state attorneys general alaska indiana montana new hampshire south carolina tennessee texas washington september johnson johnson jpi contacted texas colorado attorney generals offices behalf approximately states regarding multistate attorney general investigation october company announced proposed agreement principle would include company paying billion settlement matters october company agreed contribute additional billion allin settlement amount would resolve opioid lawsuits filed future claims states cities counties tribal governments total billion accrued subject various conditions agreement finalized agreement principle admission liability wrongdoing july company announced terms agreement settle state subdivision claims finalized onethird allin settlement expected paid within next months depending upon level participation states subdivisions terms provide period time states elect participate agreement thereafter period subdivisions participating states optin january states five territories district columbia elected participate settlement subdivision optin period expired january company retains right optout agreement late february sole discretion insufficient participation based expected participation company committed advance proceed settlement five participating states new york texas florida nevada new mexico tribal governments whose cases scheduled trial june december companys board directors received series shareholder demand letters alleging breaches fiduciary duties related marketing opioids board retained independent counsel investigate allegations demands april independent counsel delivered report board recommending company reject shareholder demands take steps necessary appropriate secure dismissal related derivative litigation board unanimously adopted recommendations independent counsels report november one shareholders sent demand filed derivative complaint johnson johnson nominal defendant certain current former directors officers defendants superior court new jersey complaint alleges breaches fiduciary duties related marketing opioids johnson johnson suffered damages result alleged breaches may shareholder filed amended complaint challenging boards rejection demand august johnson johnson moved dismiss amended complaint february court held oral argument johnson johnsons motion february court granted johnson johnsons motion dismiss amended complaint august another shareholder sent demand filed separate derivative complaint court making similar allegations october court granted defendants request reassign secondfiled case division firstfiled case pending december two additional shareholders sent demands filed two separate derivative complaints making similar allegations johnson johnson nominal defendant certain current former directors officers defendants united states district district new jersey april two federal cases consolidated single action captioned johnson johnson opioid stockholder derivative litigation july shareholders filed consolidated complaint september johnson johnson moved dismiss consolidated complaint december shareholders opposed johnson johnsons motion johnson johnson filed reply february july additional shareholder sent demand filed derivative complaint federal court making similar allegations defendants named consolidated action january pursuant order consolidated action third case consolidated consolidated action february court granted shareholders motion voluntarily dismiss consolidated action without prejudice shareholders counsel filed notice association firstfiled derivative action pending superior court new jerseyother august depuy orthopaedics inc depuy inc known depuy synthes inc johnson johnson services inc collectively depuy received informal request united states attorneys office district massachusetts civil division united states department justice united states production materials relating depuy asr xl hip device july united states notified united states district court district massachusetts declined intervene qui tam case filed pursuant false claims act companies concerning hip devices february district court granted companies motion dismiss prejudice unsealed qui tam complaint denied qui tam relators request leave file amended complaint qui tam relators appealed case united states court appeals first circuit july first circuit affirmed district courts dismissal part reversed part affirmed decision deny relators request file third amended complaint march depuy filed motion strike dismiss relators second amended complaint district court denied depuys motion strike dismiss july depuy filed motion reconsideration district courts july ruling november district court granted depuys motion reconsideration dismissed case prejudice district courts order unsealed december relators filed several postdismissal motions including january omnibus motion reconsideration following district courts order dismissing case prejudice depuy filed december motion seeking recovery attorneys fees october johnson johnson contacted california attorney generals office regarding multistate attorney general investigation marketing surgical mesh products hernia urogynecological purposes johnson johnsons subsidiary ethicon inc ethicon may california washington filed civil complaints johnson johnson ethicon ethicon us llc alleging violations consumer protection statutes similar complaints filed companies following states kentucky mississippi west virginia oregon april johnson johnson ethicon settled washington case california case started trial july concluded september october johnson johnson ethicon settled multistate investigation states district columbia january court california issued statement decision finding favor state california awarded civil penalties amount million april court california denied companys motion new trial august court entered judgment respect penalties million denied attorney generals request injunctive relief company appealing penalty judgment april company settled west virginia case october company settled attorney general oregon trial kentucky matter scheduled may june mississippi attorney general filed complaint chancery court first judicial district hinds county mississippi johnson johnson johnson johnson consumer companies inc known johnson johnson consumer inc collectively jjci complaint alleges jjci violated mississippi consumer protection act failing disclose alleged health risks associated female consumers use talc contained johnsons baby powder johnsons shower shower product divested seeks injunctive monetary relief johnson johnson jjci moved summary judgment grounds states claim barred preemption trial court denied mississippi supreme court granted johnson johnson jjcis request file interlocutory appeal denial motion summary judgment late briefing oral argument completed thereafter court rejected interlocutory appeal april remanded matter trial court thereafter state moved trial setting jjci objected trial setting due ltl bankruptcy decision whether stay applied deferred ltl bankruptcy court state opposed stay argued trial court decide issues concerning stay motion trial setting jjcis objections heard november january court granted plaintiffs motion trial setting directed parties consult court administrator secure trial date process underway august jjci filed petition writ certiorari united states supreme court mississippi supreme courts ruling april state responded petition writ certiorari november jjci filed reply november united states supreme court denied petition writ certiorari december january state new mexico filed consumer protection case alleging company deceptively marketed sold talcum powder products making misrepresentations safety products presence carcinogens including asbestos state new mexico filed amended complaint march company moved dismiss certain claims amended complaint granted company filed motion partial judgment pleadings december denied company made first document production february discovery currently scheduled close april fortytwo states district columbia commenced joint investigation companys marketing talcum powder products time multistate group asserted claims company five states issued civil investigative demands seeking documents information company produced documents arizona north carolina texas washington entered confidentiality agreements company received follow requests states march janssen pharmaceuticals inc jpi received civil investigative demand united states attorneys office southern district new york related jpis contractual relationships pharmacy benefit managers period january present regard certain jpis pharmaceutical products demand issued connection investigation false claims act company provided documents response demand july johnson johnson janssen products lp served qui tam complaint pursuant false claims act filed united states district court district new jersey alleging offlabel promotion two hiv products prezista intelence antikickback violations connection promotion products complaint filed seal december federal state governments declined intervene lawsuit prosecuted relators court denied summary judgment claims december daubert motions granted part denied part january case proceeding trial march janssen biotech inc jbi received civil investigative demand united states department justice regarding false claims act investigation concerning management advisory services provided rheumatology gastroenterology practices purchased remicade simponi aria august united states department justice notified jbi closing investigation subsequently united states district court district massachusetts unsealed qui tam false claims act complaint served company department justice declined intervene qui tam lawsuit august company filed motion dismiss granted part denied part discovery underway april september johnson johnson received subpoenas united states attorney district massachusetts seeking documents broadly relating pharmaceutical copayment support programs darzalex olysio remicade simponi stelara zytiga subpoenas also seek documents relating average manufacturer price best price reporting center medicare medicaid services related products well rebate payments state medicaid agencies company provided documents response subpoenas june johnson johnson received subpoena united states attorneys office district massachusetts seeking information regarding practices pertaining sterilization depuy synthes incdepuy spinal implants three hospitals boston well interactions employees company subsidiaries physicians hospitals johnson johnson depuy produced documents response subpoena fully cooperating governments investigation july public prosecution service rio de janeiro representatives brazilian antitrust authority cade inspected offices companies including johnson johnson brasil indstria e comrcio de produtos para sade ltda authorities appear investigating allegations possible anticompetitive behavior possible improper payments medical device industry company continues respond inquiries regarding foreign corrupt practices act united states department justice united states securities exchange commission time time company received requests variety united states congressional committees produce information relevant ongoing congressional inquiries policy johnson johnson cooperate inquiries producing requested information general litigation march april putative class action complaints filed contact lens patients number courts around united states johnson johnson vision care inc jjvci contact lens manufacturers distributors retailers alleging vertical horizontal conspiracies fix retail prices contact lenses complaints allege manufacturers reached agreements certain distributors retailers concerning prices contact lenses could sold consumers plaintiffs seeking damages injunctive relief class action cases transferred united states district court middle district florida june plaintiffs filed consolidated class action complaint november discovery pretrial motion practice complete trial isscheduled begin march beginning september multiple purported class actions filed behalf indirect purchasers remicade johnson johnson janssen biotech inc collectively janssen alleging janssen violated federal antitrust laws contracting strategies remicade cases consolidated pretrial purposes remicade antitrust litigation united states district court eastern district pennsylvania consolidated complaint seeks damages injunctive relief discovery ongoing june walgreen co kroger co filed antitrust complaint johnson johnson janssen biotech inc collectively janssen united states district court eastern district pennsylvania complaint alleges janssen violated federal antitrust laws contracting strategies remicade complaint seeks damages injunctive relief march summary judgment granted favor janssen february united states court appeals third circuit reversed district courts decision matter settled january june united states federal trade commission ftc issued civil investigative demand johnson johnson connection investigation whether janssens remicade contracting practices violate federal antitrust laws company produced documents information responsive civil investigative demand october certain united states service members families brought complaint number pharmaceutical medical devices companies including johnson johnson certain subsidiaries united states district court district columbia alleging defendants violated united states antiterrorism act complaint alleges defendants provided funding terrorist organizations sales practices pursuant pharmaceutical medical device contracts iraqi ministry health july district court dismissed complaint january united states court appeals district columbia circuit reversed district courts decision october two separate putative class actions filed actelion pharmaceutical ltd actelion pharmaceuticals us inc actelion clinical research inc collectively actelion united states district court district maryland united states district court district columbia complaints allege actelion violated state federal antitrust unfair competition laws allegedly refusing supply generic pharmaceutical manufacturers samples tracleer tracleer subject risk evaluation mitigation strategy required food drug administration imposes restrictions distribution product january plaintiffs dismissed district columbia case filed consolidated complaint united states district court district maryland october court granted actelions motion dismiss amended complaint april united states court appeals fourth circuit reversed remanded discovery ongoing december janssen biotech inc janssen oncology inc janssen research development llc johnson johnson collectively janssen served qui tam complaint filed behalf united states states district columbia complaint filed december united states district court northern district california alleges janssen violated federal false claims act state law providing pricing information zytiga government connection direct government sales governmentfunded drug reimbursement programs time federal state governments declined intervene case transferred united states district court district new jersey janssens motion dismiss denied december may class action antitrust complaint filed janssen rd ireland janssen johnson johnson united states district court northern district california complaint alleges janssen violated federal state antitrust consumer protection laws agreeing exclusivity provisions agreements gilead concerning development marketing combination antiretroviral therapies cart treat hiv complaint also alleges gilead entered similar agreements bristolmyers squibb japan tobacco march court granted part denied part defendants motions dismiss plaintiffs filed amended complaint april defendants moved dismiss amended complaint july court granted part denied part renewed motion dismiss december several insurance companies payers filed individual optout complaints containing allegations similar original complaint discovery ongoing october innovative health llc filed complaint biosense webster inc bwi united states district court middle district california complaint alleges certain bwis business practices contractual terms violate antitrust laws united states state california restricting competition sale high density mapping catheters ultrasound catheters january bwi filed motion dismiss complaint august court granted part denied part bwis motion dismiss december bwi filed motion summary judgment trial set april november johnson johnson received demand indemnification pfizer inc pursuant stock asset purchase agreement company pfizer also november johnson johnson inc received demand indemnification sanofi consumer health inc pursuant asset purchase agreement johnson johnson inc sanofi january johnson johnson received demand indemnification boehringer ingelheim pharmaceuticals inc pursuant asset purchase agreement among company pfizer boehringer ingelheim notices seek indemnification legal claims related overthecounter zantac ranitidine products plaintiffs underlying actions allege zantac overthecounter ranitidine medications contain unsafe levels ndma nnitrosodimethylamine cause andor caused various cancers patients using products seek injunctive monetary relief october fortis advisors llc fortis capacity representative former stockholders auris health inc auris filed complaint johnson johnson ethicon inc certain named officers employees collectively ethicon court chancery state delaware complaint alleges breach contract fraud causes action ethicon connection ethicons acquisition auris complaint seeks damages relief december court granted part denied part defendants motion dismiss certain causes action claims individual defendants dismissed beginning may multiple putative class actions filed state federal courts california florida new york new jersey various johnson johnson entities alleging violations state consumer fraud statutes based nondisclosure alleged benzene contamination certain neutrogena aveeno sunscreen products affirmative promotion products safe least one case alleging strict liability manufacturing defect failure warn claims asserting named plaintiffs suffered unspecified injuries result alleged exposure benzene judicial panel multidistrict litigation consolidated pending actions except one product liability case one case pending new jersey state court united states district court southern district florida fort lauderdale division october company reached agreement principle settlement nationwide class encompassing claims consolidated actions subject approval florida federal court december plaintiffs consolidated actions filed motion preliminary approval nationwide class settlement johnson johnson subsequently substituted johnson johnson consumer inc jjci along companies defendant cost recovery contribution action brought occidental chemical corporation june united states district court district new jersey related cleanup section lower passaic river new jersey johnson johnson subsidiaries also parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state local foreign laws primary relief sought cost past andor future remediation restructuring fiscal second quarter company announced plans implement series actions across global supply chain intended focus resources increase investments critical capabilities technologies solutions necessary manufacture supply product portfolio enhance agility drive growth global supply chain actions include expanding use strategic collaborations bolstering initiatives reduce complexity improve costcompetitiveness enhance capabilities optimize supply chain network fiscal year company recorded pretax charge billion included following lines consolidated statement earnings billion restructuring billion income expense billion cost products sold total project costs approximately billion recorded since restructuring announced see following table additional details restructuring program total company expects global supply chain actions generate approximately billion billion annual pretax cost savings substantially delivered end program set completed end company expects record pretax restructuring charges approximately billion billion year period activity costs associated network optimizations exit costs accelerated depreciation amortization following table summarizes severance charges associated spending initiatives fiscal year ended asset write severance total offssales dollars millions reserve balance december activity reserve balance january current year activity charges cash settlements settled non cash reserve balance january cash outlays severance expected substantially paid next year accordance company 's plans local laws includes project expense salaries employees supporting initiatives consulting expenses company continuously reevaluates severance reserves related restructuring timing payments due planned release associates regarding several longerterm projects company believes existing severance reserves sufficient cover global supply chain plans given period actions take place company continue assess make adjustments necessary additional amounts become probable estimable report independent registered public accounting firm board directors shareholders johnson johnson opinions financial statements internal control financial reporting audited accompanying consolidated balance sheets johnson johnson subsidiaries company january january related consolidated statements earnings comprehensive income equity cash flows three fiscal years period ended january including related notes collectively referred consolidated financial statements also audited company 's internal control financial reporting january based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso opinion consolidated financial statements referred present fairly material respects financial position company january january results operations cash flows three fiscal years period ended january conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting january based criteria established internal control integrated framework issued coso basis opinions company 's management responsible consolidated financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinions companys consolidated financial statements company 's internal control financial reporting based audits public accounting firm registered public company accounting oversight board united states pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audits obtain reasonable assurance whether consolidated financial statements free material misstatement whether due error fraud whether effective internal control financial reporting maintained material respects audits consolidated financial statements included performing procedures assess risks material misstatement consolidated financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures consolidated financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation consolidated financial statements audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deterioratecritical audit matters critical audit matters communicated matters arising current period audit consolidated financial statements communicated required communicated audit committee relate accounts disclosures material consolidated financial statements ii involved especially challenging subjective complex judgments communication critical audit matters alter way opinion consolidated financial statements taken whole communicating critical audit matters providing separate opinions critical audit matters accounts disclosures relate us pharmaceutical rebate reserves managed care medicare medicaid described note consolidated financial statements company recognizes revenue product sales obligations terms contract customer satisfied rebates discounts provided customers accounted variable consideration recorded reduction sales liability rebates discounts recognized within accrued rebates returns promotions consolidated balance sheet significant portion liability related rebates sale pharmaceutical goods within us primarily managed care medicare medicaid programs amounted billion january significant rebate programs include us managed care medicare medicaid rebate programs rebates discounts estimated management based contractual terms historical experience patient outcomes trend analysis projected market conditions us pharmaceutical market principal considerations determination performing procedures relating us pharmaceutical rebate reserves managed care medicare medicaid critical audit matter significant judgment management due significant measurement uncertainty involved developing reserves high degree auditor judgment subjectivity audit effort performing procedures evaluating assumptions related contractual terms historical experience patient outcomes trend analysis projected market conditions us pharmaceutical market addressing matter involved performing procedures evaluating audit evidence connection forming overall opinion consolidated financial statements procedures included testing effectiveness controls relating us pharmaceutical rebate reserves managed care medicare medicaid including controls assumptions used estimate rebates procedures also included among others developing independent estimate rebates utilizing third party information price market conditions us pharmaceutical market terms specific rebate programs historical experience trend analysis actual rebate claims paid ii testing rebate claims processed company including evaluating claims consistency contractual mandated terms companys rebate arrangements iii comparing independent estimates managements estimates litigation contingencies talc described notes consolidated financial statements company records accruals loss contingencies associated legal matters including talc probable liability incurred amount loss reasonably estimated extent adverse awards judgments verdicts rendered company management record accrual loss determined probable reasonably estimated matters management unable estimate possible loss range loss beyond amounts accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions including timing related payments ability make estimates judgments affected various factors including among things whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute procedural jurisdictional issues uncertainty unpredictability number potential claims ability achieve comprehensive multiparty settlements complexity related crossclaims counterclaims andor numerous parties involved management continues believe company strong legal grounds contest talc verdicts appealed notwithstanding managements confidence safety companys talc products certain circumstances company settled cases october johnson johnson consumer inc old jjci whollyowned subsidiary johnson johnson implemented corporate restructuring created subsidiary ltl management llc ltl became solely responsible talcrelated liabilities another subsidiary new jjci became responsible remaining business old jjci ltl filed voluntary petition seeking relief chapter bankruptcy code result ltl bankruptcy case court entered temporary restraining order staying litigation ltl old jjci november north carolina bankruptcy court confirmed scope stay issuing preliminary injunction pi prohibiting enjoining commencement prosecution talcrelated claims ltl old jjci new jjci johnson johnson corporate affiliates identified retailers insurance companies certain parties claimants filed motion dismiss ltl bankruptcy case court commenced hearing february regarding motion dismiss whether pi extended company agreed provide funding ltl payment amounts bankruptcy court determines owed ltl establishment billion trust furtherance purpose company established reserve approximately billion connection aforementioned trust parties yet able reach aresolution matters related talc certain amounts various scenarios recently referred testimony part ltl bankruptcy proceedings company unable estimate possible loss range loss beyond amount accrued principal considerations determination performing procedures relating talc litigation critical audit matter significant judgment management assessing likelihood loss incurred determining whether reasonable estimate loss range loss future existing talc claims made turn led high degree auditor judgment subjectivity effort performing procedures evaluating managements assessment loss contingencies associated litigation addressing matter involved performing procedures evaluating audit evidence connection forming overall opinion consolidated financial statements procedures included testing effectiveness controls relating managements evaluation talc litigation including controls determining whether loss probable whether amount loss reasonably estimated well financial statement disclosures procedures also included among others gaining understanding companys process around accounting reporting talc litigation ii discussing status significant known actual potential litigation ongoing ltl bankruptcy proceedings companys inhouse legal counsel well external counsel deemed necessary iii obtaining evaluating letters audit inquiry internal external legal counsel significant litigation iv evaluating reasonableness managements assessment regarding whether unfavorable outcome reasonably possible probable reasonably estimable v evaluating sufficiency companys litigation contingencies disclosures litigation opioids described notes consolidated financial statements company records accruals loss contingencies associated legal matters including opioids probable liability incurred amount loss reasonably estimated extent adverse awards judgments verdicts rendered company management record accrual loss determined probable reasonably estimated matters management unable estimate possible loss range loss beyond amounts accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions including timing related payments ability make estimates judgments affected various factors including among things whether damages sought proceedings unsubstantiated indeterminate matters present legal uncertainties significant facts dispute procedural jurisdictional issues uncertainty unpredictability number potential claims ability achieve comprehensive multiparty settlements complexity related crossclaims counterclaims andor numerous parties involved company named numerous lawsuits brought certain state local governments including tribal governments related opioids matters october company announced proposed agreement principle would include company paying billion settlement matters october company agreed contribute additional billion allin settlement amount would resolve opioid lawsuits filed future claims states cities counties tribal governments total billion july company announced terms agreement settle state subdivision claims finalized depending upon level participation various parties terms provide period time states elect participate agreement thereafter period subdivisions participating states optin subdivision optin period expired january company retains right optout agreement late february sole discretion insufficient participation principal considerations determination performing procedures relating opioids litigation critical audit matter significant judgment management determining whether reasonable estimate range loss agreement settle opioids litigation made turn led high degree auditor judgment subjectivity effort performing procedures evaluating managements assessment loss contingencies associated litigation addressing matter involved performing procedures evaluating audit evidence connection forming overall opinion consolidated financial statements procedures included testing effectiveness controls relating managements evaluation opioid litigation including controls determining whether loss probable whether amount loss reasonably estimated well financial statement disclosures procedures also included among others gaining understanding companys process around accounting reporting opioids litigation ii discussing status significant known actual potential litigation ongoing settlement negotiations companys inhouse legal counsel well external counsel deemed necessary iii obtaining evaluating letters audit inquiry internal external legal counsel significant litigation iv evaluating reasonableness managements assessment regarding whether unfavorable outcome reasonably possible probable reasonably estimable v evaluating sufficiency companys litigation contingencies disclosures pricewaterhousecoopers llp florham park new jerseyfebruary served companys auditor since least able determine specific year began serving auditor company managements report internal control financial reporting section sarbanesoxley act management required assess effectiveness companys internal control financial reporting end fiscal year report based assessment whether companys internal control financial reporting effective management company responsible establishing maintaining adequate internal control financial reporting companys internal control financial reporting designed provide reasonable assurance reliability companys financial reporting preparation external financial statements accordance generally accepted accounting principles internal controls financial reporting matter well designed inherent limitations therefore internal control financial reporting determined effective provide reasonable assurance respect financial statement preparation may prevent detect misstatements moreover projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate companys management assessed effectiveness companys internal control financial reporting january making assessment company used criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework criteria areas control environment risk assessment control activities information communication monitoring companys assessment included extensive documenting evaluating testing design operating effectiveness internal controls financial reporting based companys processes assessment described management concluded january companys internal control financial reporting effective effectiveness companys internal control financial reporting january audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein j duato joseph j wolk joaquin duato joseph j wolk director executive vice president chief financial officer chief executive officer shareholder return performance graphs set forth line graphs comparing cumulative total shareholder return companys common stock periods five years ten years ending january cumulative total return standard poors stock index standard poors pharmaceutical index standard poors healthcare equipment index graphs tables assume invested december december companys common stock standard poors stock index standard poors pharmaceutical index standard poors healthcare equipment index dividends reinvested year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceutical index sp healthcare equipment index year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceutical index sp healthcare equipment index item changes disagreements accountants accounting financial disclosure applicable item controls procedures disclosure controls procedures end period covered report company evaluated effectiveness design operation disclosure controls procedures companys disclosure controls procedures designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified secs rules forms disclosure controls procedures include without limitation controls procedures designed ensure information required disclosed company reports files submits exchange act accumulated communicated companys management including principal executive principal financial officers persons performing similar functions appropriate allow timely decisions regarding required disclosure joaquin duato chief executive officer joseph j wolk executive vice president chief financial officer reviewed participated evaluation based evaluation messrs duato wolk concluded end period covered report companys disclosure controls procedures effective reports internal control financial reporting information called item incorporated herein reference managements report internal control financial reporting attestation regarding internal controls financial reporting included report independent registered public accounting firm included item report changes internal control financial reporting fiscal quarter ended january changes companys internal control financial reporting identified connection evaluation required rules exchange act materially affected reasonably likely materially affect companys internal control financial reporting company experienced material impact internal controls financial reporting despite fact many employees worked remotely due covid pandemic company proactively took actions reevaluate refine financial reporting process additional monitoring controls provide reasonable assurance financial results reported accurately timely company continues monitor assess effectiveness design operation disclosure controls procedures company implementing multiyear enterprisewide initiative integrate simplify standardize processes systems human resources information technology procurement supply chain finance functions enhancements support growth companys financial shared service capabilities standardize financial systems initiative response identified deficiency weakness companys internal control financial reporting response initiative company continue align streamline design operation financial control environment item b information applicable item c disclosure regarding foreign jurisdictions prevent inspections applicable part iii item directors executive officers corporate governance information called item incorporated herein reference discussion audit committee caption item election directors board committees material captions item election directors applicable stock ownership section compliance delinquent section reports proxy statement material caption executive officers registrant part report companys code business conduct covers employees including chief executive officer chief financial officer controller meets requirements sec rules promulgated section thesarbanesoxley act code business conduct available companys website wwwjnjcomcode ofbusinessconduct copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendment code business conduct waiver code granted chief executive officer chief financial officer controller posted companys website wwwinvestorjnjcomgovcfm within five business days retained website least one year addition company adopted code business conduct ethics members board directors executive officers code business conduct ethics members board directors executive officers available companys website wwwinvestorjnjcomgovboardconductcfm copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendment code waiver code granted member board directors executive officer posted companys website wwwinvestorjnjcomgovcfm within five business days retained website least one year item executive compensation information called item incorporated herein reference material captions item election directors director compensation item compensation benefits committee report compensation discussion analysis executive compensation tables proxy statement material incorporated herein reference material caption compensation benefits committee report proxy statement shall deemed furnished filed report shall deemed incorporated reference filing securities act amended securities exchange act amended result furnishing except extent company specifically incorporates reference item security ownership certain beneficial owners management related stockholder matters information called item incorporated herein reference material caption item stock ownership section compliance proxy statement note common stock stock option plans stock compensation agreements notes consolidated financial statements item report equity compensation plan information following table provides certain information january concerning shares companys common stock may issued existing equity compensation plans number securities weighted issued upon average exercise exercise price number securities outstanding outstanding remaining available options options future issuance equity plan category rights rights compensation plans equity compensation plans approved security holders equity compensation plans approved security holders total included category following equity compensation plans approved companys shareholders longterm incentive plan longterm incentive plan column excludes shares reflected column number securities issued upon exercise outstanding options rights longterm incentive plan expired april options restricted shares granted subsequent date longterm incentive plan item certain relationships related transactions director independence information called item incorporated herein reference material captions item election directors director independence related person transactions proxy statement item principal accountant fees services information called item incorporated herein reference material caption item ratification appointment independent registered public accounting firm proxy statementpart iv item exhibits financial statement schedules following documents filed part report financial statements consolidated balance sheets end fiscal years consolidated statements earnings fiscal years consolidated statements comprehensive income fiscal years consolidated statements equity fiscal years consolidated statements cash flows fiscal years notes consolidated financial statements report independent registered public accounting firm schedules omitted applicable required information included financial statements notes exhibits required filed item l regulation sk information called item incorporated herein reference exhibit index report item summary registrants may voluntarily include summary information required item company elected include summary information signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized johnson johnson registrant date february j duato j duato director chief executive officer pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signature title date j duato director february j duato chief executive officer principal executive officer chief financial officer j j wolk february j j wolk principal financial officer controller chief accounting officer r j decker jr february r j decker jr principal accounting officer gorsky executive chairman board directors february gorsky director c beckerle february c beckerle director davis february davis director e l davis february e l davis director j doudna february j doudna signature title date hewson director february hewson h joly director february h joly b mcclellan director february b mcclellan director mulcahy february mulcahy director c prince february c prince director e washington february e washington director weinberger february weinberger ny west director february n west director r williams february r williams exhibit indexreg sk exhibit table description item exhibit restated certificate incorporation effective february incorporated herein reference exhibit registrants annual report fiscal year ended january ii certificate amendment certificate incorporation johnson johnson effective april incorporated herein reference exhibit registrant 's form k current report filed april iii bylaws company amended effective june incorporated herein reference exhibit registrants form k current report filed june upon request securities exchange commission registrant furnish copy instruments defining rights holders longterm debt registrant b description securities registered pursuant section securities exchange act incorporated herein reference exhibit registrants form k current report filed august longterm incentive plan incorporated herein reference exhibit registrants registration statement filed may file b form stock option certificate longterm incentive plan incorporated herein reference exhibit registrants form k current report filed january c longterm incentive plan incorporated herein reference appendix registrants proxy statement filed march form stock option certificate restricted share unit certificate performance share unit certificate longterm incentive plan incorporated herein reference